

1 **Ten variants associated with risk of estrogen receptor negative breast cancer**

2 Roger L. Milne<sup>†,1,2,\*</sup>, Karoline B. Kuchenbaecker<sup>†,3,4</sup>, Kyriaki Michailidou<sup>†,3,5</sup>, Jonathan  
3 Beesley<sup>6</sup>, Siddhartha Kar<sup>7</sup>, Sara Lindström<sup>8,9</sup>, Shirley Hui<sup>10</sup>, Audrey Lemaçon<sup>11</sup>,  
4 Penny Soucy<sup>11</sup>, Joe Dennis<sup>3</sup>, Xia Jiang<sup>9</sup>, Asha Rostamianfar<sup>10</sup>, Hilary Finucane<sup>9,12</sup>,  
5 Manjeet K. Bolla<sup>3</sup>, Lesley McGuffog<sup>3</sup>, Qin Wang<sup>3</sup>, Cora M. Aalfs<sup>13</sup>, ABCTB  
6 Investigators<sup>14</sup>, Marcia Adams<sup>15</sup>, Julian Adlard<sup>16</sup>, Simona Agata<sup>17</sup>, Shahana Ahmed<sup>7</sup>,  
7 Kristiina Aittomäki<sup>18</sup>, Fares Al-Ejeh<sup>19</sup>, Jamie Allen<sup>3</sup>, Christine B. Ambrosone<sup>20</sup>,  
8 Christopher I. Amos<sup>21</sup>, Irene L. Andrulis<sup>22,23</sup>, Hoda Anton-Culver<sup>24</sup>, Natalia N.  
9 Antonenkova<sup>25</sup>, Volker Arndt<sup>26</sup>, Norbert Arnold<sup>27</sup>, Kristan J. Aronson<sup>28</sup>, Bernd  
10 Auber<sup>29</sup>, Paul L. Auer<sup>30,31</sup>, Margreet G.E.M. Ausems<sup>32</sup>, Jacopo Azzollini<sup>33</sup>, François  
11 Bacot<sup>34</sup>, Judith Balmaña<sup>35</sup>, Monica Barile<sup>36</sup>, Laure Barjhoux<sup>37</sup>, Rosa B.  
12 Barkardottir<sup>38,39</sup>, Myrto Barrdahl<sup>40</sup>, Daniel Barnes<sup>3</sup>, Daniel Barrowdale<sup>3</sup>, Caroline  
13 Baynes<sup>7</sup>, Matthias W. Beckmann<sup>41</sup>, Javier Benitez<sup>42-44</sup>, Marina Bermisheva<sup>45</sup>, Leslie  
14 Bernstein<sup>46</sup>, Yves-Jean Bignon<sup>47</sup>, Kathleen R. Blazer<sup>48</sup>, Marinus J. Blok<sup>49</sup>, Carl  
15 Blomqvist<sup>50</sup>, William Blot<sup>51,52</sup>, Kristie Bobolis<sup>53</sup>, Bram Boeckx<sup>54,55</sup>, Natalia V.  
16 Bogdanova<sup>25,56,57</sup>, Stig E. Bojesen<sup>58-60</sup>, Anders Bojesen<sup>61</sup>, Bernardo Bonanni<sup>36</sup>,  
17 Anne-Lise Børresen-Dale<sup>62</sup>, Aniko Bozsik<sup>63</sup>, Angela R. Bradbury<sup>64</sup>, Judith S. Brand<sup>65</sup>,  
18 Hiltrud Brauch<sup>66-68</sup>, Hermann Brenner<sup>26,68,69</sup>, Brigitte Bressac-de Paillerets<sup>70</sup>, Carole  
19 Brewer<sup>71</sup>, Louise Brinton<sup>72</sup>, Per Broberg<sup>73</sup>, Angela Brooks-Wilson<sup>74,75</sup>, Joan Brunet<sup>76</sup>,  
20 Thomas Brüning<sup>77</sup>, Barbara Burwinkel<sup>78,79</sup>, Saundra S. Buys<sup>80</sup>, Jinyoung Byun<sup>21</sup>,  
21 Qiuyin Cai<sup>51</sup>, Trinidad Caldes<sup>81</sup>, Maria A. Caligo<sup>82</sup>, Ian Campbell<sup>83,84</sup>, Federico  
22 Canzian<sup>85</sup>, Olivier Caron<sup>70</sup>, Angel Carracedo<sup>86,87</sup>, Brian D. Carter<sup>88</sup>, J. Esteban  
23 Castela<sup>89</sup>, Laurent Castera<sup>90</sup>, Virginie Caux-Moncoutier<sup>91</sup>, Salina B. Chan<sup>92</sup>, Jenny  
24 Chang-Claude<sup>40,93</sup>, Stephen J. Chanock<sup>72</sup>, Xiaoqing Chen<sup>6</sup>, Ting-Yuan David  
25 Cheng<sup>94</sup>, Jocelyne Chiquette<sup>95</sup>, Hans Christiansen<sup>56</sup>, Kathleen B.M. Claes<sup>96</sup>,  
26 Christine L. Clarke<sup>97</sup>, NBCS Collaborators<sup>62,98-109</sup>, Thomas Conner<sup>110</sup>, Don M.  
27 Conroy<sup>7</sup>, Jackie Cook<sup>111</sup>, Emilie Cordina-Duverger<sup>112</sup>, Sten Cornelissen<sup>113</sup>, Isabelle  
28 Coupier<sup>114</sup>, David Cox<sup>115,116</sup>, Angela Cox<sup>117</sup>, Simon S. Cross<sup>118</sup>, Katarina Cuk<sup>26</sup>, Julie  
29 M. Cunningham<sup>119</sup>, Kamila Czene<sup>65</sup>, Mary B. Daly<sup>120</sup>, Francesca Damiola<sup>37</sup>, Hatef  
30 Darabi<sup>65</sup>, Rosemarie Davidson<sup>121</sup>, Kim De Leeneer<sup>96</sup>, Peter Devilee<sup>122,123</sup>, Ed Dicks<sup>7</sup>,  
31 Orland Diez<sup>124</sup>, Yuan Chun Ding<sup>46</sup>, Nina Ditsch<sup>125</sup>, Kimberly F. Doherty<sup>15</sup>, Susan M.  
32 Domchek<sup>64</sup>, Cecilia M. Dorfling<sup>126</sup>, Thilo Dörk<sup>57</sup>, Isabel dos-Santos-Silva<sup>127</sup>,  
33 Stéphane Dubois<sup>11</sup>, Pierre-Antoine Dugué<sup>1,2</sup>, Martine Dumont<sup>11</sup>, Alison M. Dunning<sup>7</sup>,  
34 Lorraine Durcan<sup>128,129</sup>, Miriam Dwek<sup>130</sup>, Bernd Dworniczak<sup>131</sup>, Diana Eccles<sup>129</sup>, Ros  
35 Eeles<sup>132</sup>, Hans Ehrencrona<sup>133</sup>, Ursula Eilber<sup>40</sup>, Bent Ejlersen<sup>134</sup>, Arif B. Ekici<sup>135</sup>, A.  
36 Heather Eliassen<sup>136,137</sup>, EMBRACE<sup>3</sup>, Christoph Engel<sup>138,139</sup>, Mikael Eriksson<sup>65</sup>,  
37 Laura Fachal<sup>7</sup>, Laurence Faivre<sup>140,141</sup>, Peter A. Fasching<sup>41,142</sup>, Ulrike Faust<sup>143</sup>, Jonine  
38 Figueroa<sup>72,144</sup>, Dieter Flesch-Janys<sup>145,146</sup>, Olivia Fletcher<sup>147</sup>, Henrik Flyger<sup>148</sup>, William  
39 D. Foulkes<sup>149</sup>, Eitan Friedman<sup>150,151</sup>, Lin Fritschi<sup>152</sup>, Debra Frost<sup>3</sup>, Marike  
40 Gabrielson<sup>65</sup>, Pragna Gaddam<sup>153</sup>, Patricia A. Ganz<sup>154</sup>, Susan M. Gapstur<sup>88</sup>, Judy  
41 Garber<sup>155</sup>, Vanesa Garcia-Barberan<sup>81</sup>, José A. García-Sáenz<sup>81</sup>, Mia M. Gaudet<sup>88</sup>,  
42 Marion Gauthier-Villars<sup>91</sup>, Andrea Gehrig<sup>156</sup>, GEMO Study Collaborators<sup>157,158</sup>,  
43 Vassilios Georgoulas<sup>159</sup>, Anne-Marie Gerdes<sup>160</sup>, Graham G. Giles<sup>1,2</sup>, Gord

44 Glendon<sup>22</sup>, Andrew K Godwin<sup>161</sup>, Mark S. Goldberg<sup>162,163</sup>, David E. Goldgar<sup>164</sup>, Anna  
 45 González-Neira<sup>42</sup>, Paul Goodfellow<sup>165</sup>, Mark H. Greene<sup>166</sup>, Grethe I. Grenaker  
 46 Alnæs<sup>62</sup>, Mervi Grip<sup>167</sup>, Jacek Gronwald<sup>168</sup>, Anne Grundy<sup>169</sup>, Daphne Gschwantler-  
 47 Kaulich<sup>170</sup>, Pascal Guénel<sup>112</sup>, Qi Guo<sup>7</sup>, Lothar Haeberle<sup>41</sup>, Eric Hahnen<sup>171-173</sup>,  
 48 Christopher A. Haiman<sup>174</sup>, Niclas Håkansson<sup>175</sup>, Emily Hallberg<sup>176</sup>, Ute Hamann<sup>177</sup>,  
 49 Natalie Hammell<sup>34</sup>, Susan Hankinson<sup>178</sup>, Thomas V.O. Hansen<sup>179</sup>, Patricia  
 50 Harrington<sup>7</sup>, Steven N. Hart<sup>176</sup>, Jaana M. Hartikainen<sup>180-182</sup>, Catherine S. Healey<sup>7</sup>,  
 51 HEBON<sup>183</sup>, Alexander Hein<sup>41</sup>, Sonja Helbig<sup>57</sup>, Alex Henderson<sup>184</sup>, Jane Heyworth<sup>185</sup>,  
 52 Belynda Hicks<sup>186</sup>, Peter Hillemanns<sup>57</sup>, Shirley Hodgson<sup>187</sup>, Frans B. Hogervorst<sup>188</sup>,  
 53 Antoinette Hollestelle<sup>189</sup>, Maartje J. Hooning<sup>189</sup>, Bob Hoover<sup>72</sup>, John L. Hopper<sup>2</sup>,  
 54 Chunling Hu<sup>119</sup>, Guanmengqian Huang<sup>177</sup>, Peter J. Hulick<sup>190,191</sup>, Keith Humphreys<sup>65</sup>,  
 55 David J. Hunter<sup>9,137</sup>, Evgeny N. Imyanitov<sup>192</sup>, Claudine Isaacs<sup>193</sup>, Motoki Iwasaki<sup>194</sup>,  
 56 Louise Izatt<sup>195</sup>, Anna Jakubowska<sup>168</sup>, Paul James<sup>84,196</sup>, Ramunas Janavicius<sup>196,197</sup>,  
 57 Wolfgang Janni<sup>198</sup>, Uffe Birk Jensen<sup>199</sup>, Esther M. John<sup>200,201</sup>, Nichola Johnson<sup>147</sup>,  
 58 Michael Jones<sup>202</sup>, Kristine Jones<sup>186</sup>, Arja Jukkola-Vuorinen<sup>203</sup>, Rudolf Kaaks<sup>40</sup>, Maria  
 59 Kabisch<sup>177</sup>, Katarzyna Kaczmarek<sup>168</sup>, Daehee Kang<sup>204-206</sup>, Karin Kast<sup>207</sup>,  
 60 kConFab/AOCS Investigators<sup>6,83,84</sup>, Renske Keeman<sup>113</sup>, Michael J. Kerin<sup>208</sup>, Carolien  
 61 M. Kets<sup>209</sup>, Machteld Keupers<sup>210</sup>, Sofia Khan<sup>211</sup>, Elza Khusnutdinova<sup>45,212</sup>, Johanna I.  
 62 Kiiski<sup>211</sup>, Sung-Won Kim<sup>170</sup>, Julia A. Knight<sup>213,214</sup>, Irene Konstantopoulou<sup>215</sup>, Veli-  
 63 Matti Kosma<sup>180-182</sup>, Vessela N. Kristensen<sup>62,103,216</sup>, Torben A. Kruse<sup>217</sup>, Ava  
 64 Kwong<sup>218-220</sup>, Anne-Vibeke Lænkholm<sup>221</sup>, Yael Laitman<sup>150</sup>, Fiona Laloo<sup>222</sup>, Diether  
 65 Lambrechts<sup>54,55</sup>, Keren Landsman<sup>223</sup>, Christine Lasset<sup>224</sup>, Conxi Lazaro<sup>225</sup>, Loic Le  
 66 Marchand<sup>226</sup>, Julie Lecarpentier<sup>3</sup>, Eunjung Lee<sup>174</sup>, Jong Won Lee<sup>227</sup>, Andrew Lee<sup>3</sup>,  
 67 Min Hyuk Lee<sup>228</sup>, Flavio Lejbkowitz<sup>223</sup>, Fabienne Lesueur<sup>229-232</sup>, Jingmei Li<sup>65</sup>, Jenna  
 68 Lilyquist<sup>233</sup>, Anne Lincoln<sup>234</sup>, Annika Lindblom<sup>235</sup>, Jolanta Lissowska<sup>236</sup>, Wing-Yee  
 69 Lo<sup>66,67</sup>, Sibylle Loibl<sup>237</sup>, Jirong Long<sup>51</sup>, Jennifer T. Loud<sup>166</sup>, Jan Lubinski<sup>168</sup>, Craig  
 70 Luccarini<sup>7</sup>, Michael Lush<sup>3</sup>, Robert J. MacInnis<sup>1,2</sup>, Tom Maishman<sup>128,129</sup>, Enes  
 71 Makalic<sup>2</sup>, Ivana Maleva Kostovska<sup>238</sup>, Siranoush Manoukian<sup>33</sup>, JoAnn E. Manson<sup>239</sup>,  
 72 Sara Margolin<sup>240</sup>, John W.M. Martens<sup>189</sup>, Maria Elena Martinez<sup>241,242</sup>, Keitaro  
 73 Matsuo<sup>243,244</sup>, Dimitrios Mavroudis<sup>159</sup>, Sylvie Mazoyer<sup>245</sup>, Catriona McLean<sup>246</sup>, Hanne  
 74 Meijers-Heijboer<sup>247</sup>, Primitiva Menéndez<sup>248</sup>, Jeffery Meyer<sup>119</sup>, Hui Miao<sup>249</sup>, Nicola  
 75 Miller<sup>208</sup>, Austin Miller<sup>250</sup>, Gillian Mitchell<sup>84,196</sup>, Marco Montagna<sup>17</sup>, Kenneth  
 76 Muir<sup>251,252</sup>, Anna Marie Mulligan<sup>253,254</sup>, Claire Mulot<sup>255</sup>, Sue Nadesan<sup>53</sup>, Katherine L.  
 77 Nathanson<sup>64</sup>, Susan L. Neuhausen<sup>46</sup>, Heli Nevanlinna<sup>211</sup>, Ines Nevelsteen<sup>210</sup>, Dieter  
 78 Niederacher<sup>256</sup>, Sune F. Nielsen<sup>58,59</sup>, Børge G. Nordestgaard<sup>58-60</sup>, Aaron Norman<sup>176</sup>,  
 79 Robert L. Nussbaum<sup>257</sup>, Edith Olah<sup>63</sup>, Olufunmilayo I. Olopade<sup>258</sup>, Janet E. Olson<sup>176</sup>,  
 80 Curtis Olsowold<sup>176</sup>, Kai-ren Ong<sup>259</sup>, Jan C. Oosterwijk<sup>260</sup>, Nick Orr<sup>147</sup>, Ana Osorio<sup>43,44</sup>,  
 81 V. Shane Pankratz<sup>261</sup>, Laura Papi<sup>262</sup>, Tjong-Won Park-Simon<sup>57</sup>, Ylva Paulsson-  
 82 Karlsson<sup>263</sup>, Rachel Peake<sup>264</sup>, Inge Søkilde Pedersen<sup>265</sup>, Bernard Peissel<sup>33</sup>, Ana  
 83 Peixoto<sup>266</sup>, Jose I.A. Perez<sup>267</sup>, Paolo Peterlongo<sup>268</sup>, Julian Peto<sup>127</sup>, Georg Pfeiler<sup>170</sup>,  
 84 Catherine M. Phelan<sup>269</sup>, Mila Pinchev<sup>223</sup>, Dijana Plaseska-Karanfilska<sup>238</sup>, Bruce  
 85 Poppe<sup>96</sup>, Mary E Porteous<sup>270</sup>, Ross Prentice<sup>30</sup>, Nadege Presneau<sup>130</sup>, Darya  
 86 Prokofieva<sup>212</sup>, Elizabth Pugh<sup>15</sup>, Miquel Angel Pujana<sup>271</sup>, Katri Pykäs<sup>272,273</sup>, Brigitte  
 87 Rack<sup>125</sup>, Paolo Radice<sup>274</sup>, Nazneen Rahman<sup>275</sup>, Johanna Rantala<sup>276</sup>, Christine

88 Rappaport-Fuerhauser<sup>170</sup>, Gad Rennert<sup>223,277</sup>, Hedy S. Rennert<sup>223</sup>, Valerie Rhenius<sup>7</sup>,  
89 Kerstin Rhiem<sup>171-173</sup>, Andrea Richardson<sup>278</sup>, Gustavo C. Rodriguez<sup>279</sup>, Atocha  
90 Romero<sup>81,280</sup>, Jane Romm<sup>15</sup>, Matti A. Rookus<sup>281</sup>, Anja Rudolph<sup>40</sup>, Thomas  
91 Ruediger<sup>282</sup>, Emmanouil Saloustros<sup>283</sup>, Joyce Sanders<sup>284</sup>, Dale P. Sandler<sup>285</sup>,  
92 Suleeporn Sangrajang<sup>286</sup>, Elinor J. Sawyer<sup>287</sup>, Daniel F. Schmidt<sup>2</sup>, Minouk J.  
93 Schoemaker<sup>202</sup>, Fredrick Schumacher<sup>174</sup>, Peter Schürmann<sup>57</sup>, Lukas Schwentner<sup>198</sup>,  
94 Rodney J. Scott<sup>288,289</sup>, Christopher Scott<sup>176</sup>, Sheila Seal<sup>275</sup>, Leigha Senter<sup>290</sup>,  
95 Caroline Seynaeve<sup>189</sup>, Mitul Shah<sup>7</sup>, Priyanka Sharma<sup>291</sup>, Chen-Yang Shen<sup>292,293</sup>, Xin  
96 Sheng<sup>174</sup>, Hermela Shimelis<sup>119</sup>, Martha J. Shrubsole<sup>51</sup>, Xiao-Ou Shu<sup>51</sup>, Lucy E  
97 Side<sup>294</sup>, Christian F. Singer<sup>170</sup>, Christof Sohn<sup>295</sup>, Melissa C. Southey<sup>296</sup>, John J.  
98 Spinelli<sup>297,298</sup>, Amanda B. Spurdle<sup>6</sup>, Christa Stegmaier<sup>299</sup>, Dominique Stoppa-  
99 Lyonnet<sup>91</sup>, Grzegorz Sukiennicki<sup>168</sup>, Harald Surowy<sup>78,79</sup>, Christian Sutter<sup>300</sup>, Anthony  
100 Swerdlow<sup>202,301</sup>, Csilla I. Szabo<sup>302</sup>, Rulla M. Tamimi<sup>9,136,137</sup>, Yen Y. Tan<sup>303</sup>, Jack A.  
101 Taylor<sup>285,304</sup>, Maria-Isabel Tejada<sup>305</sup>, Maria Tengström<sup>180,306,307</sup>, Soo H. Teo<sup>308,309</sup>,  
102 Mary B. Terry<sup>310</sup>, Daniel C. Tessier<sup>34</sup>, Alex Teulé<sup>311</sup>, Kathrin Thöne<sup>146</sup>, Darcy L.  
103 Thull<sup>312</sup>, Maria Grazia Tibiletti<sup>313</sup>, Laima Tihomirova<sup>314</sup>, Marc Tischkowitz<sup>149,315</sup>,  
104 Amanda E. Toland<sup>316</sup>, Rob A.E.M. Tollenaar<sup>317</sup>, Ian Tomlinson<sup>318</sup>, Diana Torres<sup>177,319</sup>,  
105 Martine Tranchant<sup>11</sup>, Thérèse Truong<sup>112</sup>, Jonathan Tyrer<sup>7</sup>, Kathy Tucker<sup>320</sup>, Nadine  
106 Tung<sup>321</sup>, Hans-Ulrich Ulmer<sup>322</sup>, Celine Vachon<sup>176</sup>, Christi J. van Asperen<sup>323</sup>, David  
107 Van Den Berg<sup>174</sup>, Ans M.W. van den Ouweland<sup>324</sup>, Elizabeth J. van Rensburg<sup>126</sup>,  
108 Liliana Varesco<sup>325</sup>, Raymonda Varon-Mateeva<sup>326</sup>, Ana Vega<sup>327,328</sup>, Alessandra  
109 Viel<sup>329</sup>, Joseph Vijai<sup>234</sup>, Daniel Vincent<sup>34</sup>, Jason Vollenweider<sup>119</sup>, Lisa Walker<sup>330</sup>,  
110 Zhaoming Wang<sup>72,331</sup>, Shan Wang-Gohrke<sup>198</sup>, Barbara Wappenschmidt<sup>171-173</sup>, Clarice  
111 R. Weinberg<sup>332</sup>, Jeffrey N. Weitzel<sup>48</sup>, Camilla Wendt<sup>240</sup>, Jelle Wesseling<sup>113,284</sup>, Alice  
112 S. Whittemore<sup>201</sup>, Juul T. Wijnen<sup>123,323</sup>, Walter Willett<sup>137,333</sup>, Robert Winqvist<sup>272,273</sup>,  
113 Alicja Wolk<sup>175</sup>, Anna H. Wu<sup>174</sup>, Lucy Xia<sup>174</sup>, Xiaohong R. Yang<sup>72</sup>, Drakoulis  
114 Yannoukakos<sup>215</sup>, Daniela Zaffaroni<sup>33</sup>, Wei Zheng<sup>51</sup>, Bin Zhu<sup>186</sup>, Argyrios Ziogas<sup>24</sup>,  
115 Elad Ziv<sup>334</sup>, Kristin K. Zorn<sup>312</sup>, Manuela Gago-Dominguez<sup>86,241</sup>, Arto Mannermaa<sup>180-  
116 182</sup>, Håkan Olsson<sup>73</sup>, Manuel R. Teixeira<sup>266,335</sup>, Jennifer Stone<sup>264,336</sup>, Kenneth  
117 Offitt<sup>337,338</sup>, Laura Ottini<sup>339</sup>, Sue K. Park<sup>204-206</sup>, Mads Thomassen<sup>217</sup>, Per Hall<sup>65</sup>, Alfons  
118 Meindl<sup>340</sup>, Rita K. Schmutzler<sup>171-173</sup>, Arnaud Droit<sup>11</sup>, Gary D. Bader<sup>10</sup>, Paul D.P.  
119 Pharoah<sup>3,7</sup>, Fergus J. Couch<sup>119</sup>, Douglas F. Easton<sup>3,7</sup>, Peter Kraft<sup>9,137</sup>, Georgia  
120 Chenevix-Trench<sup>6</sup>, Montserrat García-Closas<sup>72</sup>, Marjanka K. Schmidt<sup>113,341</sup>,  
121 Antonis C. Antoniou<sup>3</sup>, Jacques Simard<sup>11</sup>

122 <sup>†</sup>Co-first authorship

123 <sup>#</sup>Co-senior authorship

124 \*Correspondence to: Roger L. Milne, Cancer Epidemiology Centre, Cancer Council  
125 Victoria, Melbourne, Australia; E-mail: [roger.milne@cancervic.org.au](mailto:roger.milne@cancervic.org.au).

126 1. Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia.  
127 2. Centre for Epidemiology and Biostatistics, Melbourne School of Population  
128 and Global health, The University of Melbourne, Melbourne, Australia.

- 129 3. Centre for Cancer Genetic Epidemiology, Department of Public Health and  
130 Primary Care, University of Cambridge, Cambridge, UK.
- 131 4. The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,  
132 Hinxton, Cambridge, UK.
- 133 5. Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute  
134 of Neurology and Genetics, Nicosia, Cyprus.
- 135 6. Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane,  
136 Australia.
- 137 7. Centre for Cancer Genetic Epidemiology, Department of Oncology, University  
138 of Cambridge, Cambridge, UK.
- 139 8. Department of Epidemiology, University of Washington School of Public  
140 Health, Seattle, WA, USA.
- 141 9. Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan  
142 School of Public Health, Boston, MA, USA.
- 143 10. The Donnelly Centre, University of Toronto, Toronto, Canada.
- 144 11. Genomics Center, Centre Hospitalier Universitaire de Québec Research  
145 Center, Laval University, Québec City, Canada.
- 146 12. Department of Mathematics, Massachusetts Institute of Technology,  
147 Cambridge, MA, USA.
- 148 13. Department of Clinical Genetics, Academic Medical Center, Amsterdam, The  
149 Netherlands.
- 150 14. Australian Breast Cancer Tissue Bank, Westmead Institute for Medical  
151 Research, University of Sydney, Sydney, Australia.
- 152 15. Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine,  
153 Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- 154 16. Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK.
- 155 17. Istituto Oncologico Veneto IOV - IRCCS, Immunology and Molecular  
156 Oncology Unit, Padua, Italy.
- 157 18. Department of Clinical Genetics, Helsinki University Hospital, University of  
158 Helsinki, Helsinki, Finland.
- 159 19. Personalised Medicine Team, QIMR Berghofer Medical Research Institute,  
160 Brisbane, Australia.
- 161 20. Roswell Park Cancer Institute, Buffalo, NY, USA.
- 162 21. Center for Genomic Medicine, Department of Biomedical Data Science,  
163 Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.
- 164 22. Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research  
165 Institute of Mount Sinai Hospital, Toronto, Canada.
- 166 23. Department of Molecular Genetics, University of Toronto, Toronto, Canada.
- 167 24. Department of Epidemiology, University of California Irvine, Irvine, CA, USA.
- 168 25. N.N. Alexandrov Research Institute of Oncology and Medical Radiology,  
169 Minsk, Belarus.
- 170 26. Division of Clinical Epidemiology and Aging Research, German Cancer  
171 Research Center (DKFZ), Heidelberg, Germany.
- 172 27. Department of Gynaecology and Obstetrics, University Hospital of Schleswig-  
173 Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
- 174 28. Department of Public Health Sciences, and Cancer Research Institute,  
175 Queen's University, Kingston, ON, Canada.
- 176 29. Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
- 177 30. Cancer Prevention Program, Fred Hutchinson Cancer Research Center,  
178 Seattle, WA, USA.

- 179 31. Zilber School of Public Health, University of Wisconsin-Milwaukee,  
180 Milwaukee, WI, USA.
- 181 32. Department of Medical Genetics, University Medical Center Utrecht, Utrecht,  
182 The Netherlands.
- 183 33. Unit of Medical Genetics, Department of Preventive and Predictive Medicine,  
184 Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico)  
185 Istituto Nazionale dei Tumori (INT), Milan, Italy.
- 186 34. McGill University and Génome Québec Innovation Centre, Montréal, Canada.
- 187 35. Department of Medical Oncology. University Hospital, Vall d'Hebron,  
188 Barcelona, Spain.
- 189 36. Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia,  
190 Milan, Italy.
- 191 37. Bâtiment Cheney D, Centre Léon Bérard, Lyon, France.
- 192 38. Laboratory of Cell Biology, Department of Pathology, Landspítali-LSH  
193 v/Hringbraut, Reykjavik, Iceland.
- 194 39. BMC (Biomedical Centre), Faculty of Medicine, University of Iceland,  
195 Reykjavik, Iceland.
- 196 40. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),  
197 Heidelberg, Germany.
- 198 41. Department of Gynaecology and Obstetrics, University Hospital Erlangen,  
199 Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer  
200 Center Erlangen-EMN, Erlangen, Germany.
- 201 42. Genotyping Unit, Human Cancer Genetics Programme, Spanish National  
202 Cancer Research Centre, Madrid, Spain.
- 203 43. Human Genetics Group, Human Cancer Genetics Programme, Spanish  
204 National Cancer Centre (CNIO), Madrid, Spain.
- 205 44. Spanish Network on Rare Diseases (CIBERER), Madrid, Spain.
- 206 45. Institute of Biochemistry and Genetics, Ufa Scientific Center of Russian  
207 Academy of Sciences, Ufa, Russia.
- 208 46. Department of Population Sciences, Beckman Research Institute of City of  
209 Hope, Duarte, CA, USA.
- 210 47. Department of Oncogenetics, Centre Jean Perrin, BP 392, Clermont-Ferrand,  
211 France.
- 212 48. Clinical Cancer Genetics, City of Hope, Duarte, California, USA.
- 213 49. Department of Clinical Genetics, Maastricht University Medical Center,  
214 Maastricht, The Netherlands.
- 215 50. Department of Oncology, Helsinki University Hospital, University of Helsinki,  
216 Helsinki, Finland.
- 217 51. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology  
218 Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of  
219 Medicine, Nashville, TN, USA.
- 220 52. International Epidemiology Institute, Rockville, MD, USA.
- 221 53. City of Hope Clinical Cancer Genomics Community Research Network,  
222 Duarte, CA, USA.
- 223 54. Vesalius Research Center, VIB, Leuven, Belgium.
- 224 55. Laboratory for Translational Genetics, Department of Oncology, University of  
225 Leuven, Leuven, Belgium.
- 226 56. Department of Radiation Oncology, Hannover Medical School, Hannover,  
227 Germany.
- 228 57. Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.

- 229 58. Copenhagen General Population Study, Herlev and Gentofte Hospital,  
230 Copenhagen University Hospital, Herlev, Denmark.
- 231 59. Department of Clinical Biochemistry, Herlev and Gentofte Hospital,  
232 Copenhagen University Hospital, Herlev, Denmark.
- 233 60. Faculty of Health and Medical Sciences, University of Copenhagen,  
234 Copenhagen, Denmark.
- 235 61. Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark.
- 236 62. Department of Cancer Genetics, Institute for Cancer Research, Oslo  
237 University Hospital Radiumhospitalet, Oslo, Norway.
- 238 63. Department of Molecular Genetics, National Institute of Oncology, Budapest,  
239 Hungary.
- 240 64. Department of Medicine, Abramson Cancer Center, Perelman School of  
241 Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- 242 65. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,  
243 Stockholm, Sweden.
- 244 66. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart,  
245 Germany.
- 246 67. University of Tübingen, Tübingen, Germany.
- 247 68. German Cancer Consortium (DKTK), German Cancer Research Center  
248 (DKFZ), Heidelberg, Germany.
- 249 69. Division of Preventive Oncology, German Cancer Research Center (DKFZ)  
250 and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
- 251 70. Gustave Roussy, Biopathology Department, Villejuif, F-94805, France.
- 252 71. Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, UK.
- 253 72. Division of Cancer Epidemiology and Genetics, National Cancer Institute,  
254 Rockville, MD, USA.
- 255 73. Department of Cancer Epidemiology, Clinical Sciences, Lund University,  
256 Lund, Sweden.
- 257 74. Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
- 258 75. Department of Biomedical Physiology and Kinesiology, Simon Fraser  
259 University, Burnaby, BC, Canada.
- 260 76. Genetic Counseling Unit, Hereditary Cancer Program, IDIBGI (Institut  
261 d'Investigació Biomèdica de Girona), Catalan Institute of Oncology, Girona,  
262 Spain.
- 263 77. Institute for Prevention and Occupational Medicine of the German Social  
264 Accident Insurance, Institute of the Ruhr University Bochum, Bochum,  
265 Germany.
- 266 78. Department of Obstetrics and Gynecology, University of Heidelberg,  
267 Heidelberg, Germany.
- 268 79. Molecular Epidemiology Group, C080, German Cancer Research Center  
269 (DKFZ), Heidelberg, Germany.
- 270 80. Department of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope,  
271 Salt Lake City, UT, USA.
- 272 81. Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain.
- 273 82. Section of Genetic Oncology, Dept. of Laboratory Medicine, University and  
274 University Hospital of Pisa, Pisa, Italy.
- 275 83. Research Department, Peter MacCallum Cancer Centre, East Melbourne,  
276 Australia.
- 277 84. Sir Peter MacCallum, Department of Oncology, The University of Melbourne,  
278 Melbourne, Australia.

- 279 85. Genomic Epidemiology Group, German Cancer Research Center (DKFZ),  
280 Heidelberg, Germany.
- 281 86. Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto  
282 de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo  
283 Hospitalario Universitario de Santiago, Servicio Galego de Saúde SERGAS,  
284 Santiago De Compostela, Spain.
- 285 87. Centro de Investigación en Red de Enfermedades Raras (CIBERER) y Centro  
286 Nacional de Genotipado (CEGEN-PRB2), Universidad de Santiago de  
287 Compostela, Spain.
- 288 88. Epidemiology Research Program, American Cancer Society, Atlanta, GA,  
289 USA.
- 290 89. Oncology and Genetics Unit, Instituto de Investigacion Biomedica (IBI)  
291 Orense-Pontevedra-Vigo, Xerencia de Xestion Integrada de Vigo-SERGAS,  
292 Vigo, Spain.
- 293 90. Centre François Baclesse, 3 avenue Général Harris, Caen, France.
- 294 91. Service de Génétique Oncologique, Institut Curie, Paris, France.
- 295 92. 1600 Divisadero Street, C415, San Francisco, CA, USA.
- 296 93. University Cancer Center Hamburg (UCCH), University Medical Center  
297 Hamburg-Eppendorf, Hamburg, Germany.
- 298 94. Division of Cancer Prevention and Population Sciences, Roswell Park Cancer  
299 Institute, Buffalo, NY, USA.
- 300 95. Unité de recherche en santé des populations, Centre des maladies du sein  
301 Deschênes-Fabia, Hôpital du Saint-Sacrement, Québec, Canada.
- 302 96. Center for Medical Genetics, Ghent University, Gent, Belgium.
- 303 97. Westmead Institute for Medical Research, University of Sydney, Sydney,  
304 Australia.
- 305 98. Section of Oncology, Institute of Medicine, University of Bergen and  
306 Department of Oncology, Haukeland University Hospital, Bergen, Norway.
- 307 99. Department of Pathology, Akershus University Hospital, Lørenskog, Norway.
- 308 100. Department of Breast-Endocrine Surgery, Akershus University Hospital, Oslo,  
309 Norway.
- 310 101. Department of Breast- and Endocrine Surgery, Division of Surgery, Cancer  
311 and Transplantation Medicine, Oslo University Hospital Ullevål, Oslo, Norway.
- 312 102. Department of Research, Vestre Viken, Drammen, Norway.
- 313 103. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo,  
314 Norway.
- 315 104. National Advisory Unit on Late Effects after Cancer Treatment, Department of  
316 Oncology, Oslo University Hospital, Oslo, Norway.
- 317 105. Department of Oncology, Division of Surgery and Cancer and Transplantation  
318 Medicine, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
- 319 106. Department of Radiology and Nuclear Medicine, Oslo University Hospital,  
320 Oslo, Norway.
- 321 107. Department of Oncology, Oslo University Hospital Ullevål, Oslo, Norway.
- 322 108. Department of Tumor Biology, Institute for Cancer Research, Oslo University  
323 Hospital Radiumhospitalet, Oslo, Norway.
- 324 109. Oslo University Hospital, Oslo, Norway.
- 325 110. Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT, USA.
- 326 111. Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield,  
327 UK.

- 328 112. Cancer & Environment Group, Center for Research in Epidemiology and  
329 Population Health (CESP), INSERM, University Paris-Sud, University Paris-  
330 Saclay, Villejuif, France.
- 331 113. Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni  
332 van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- 333 114. Unité d'Oncogénétique, CHU Arnaud de Villeneuve, Montpellier, France.
- 334 115. Department of Epidemiology and Biostatistics, School of Public Health,  
335 Imperial College London, London, UK.
- 336 116. INSERM U1052, Cancer Research Center of Lyon, Lyon, France.
- 337 117. Academic Unit of Molecular Oncology, Department of Oncology and  
338 Metabolism, University of Sheffield, Sheffield, UK.
- 339 118. Academic Unit of Pathology, Department of Neuroscience, University of  
340 Sheffield, Sheffield, UK.
- 341 119. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,  
342 MN, USA.
- 343 120. Department of Clinical Genetics, Timothy R. Talbot Jr. Chair  
344 for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA.
- 345 121. Department of Clinical Genetics, South Glasgow University Hospitals,  
346 Glasgow, UK.
- 347 122. Department of Pathology, Leiden University Medical Center, Leiden, The  
348 Netherlands.
- 349 123. Department of Human Genetics, Leiden University Medical Center, Leiden,  
350 The Netherlands.
- 351 124. Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Clinical and  
352 Molecular Genetics Area, Vall d'Hebron University Hospital, Barcelona, Spain.
- 353 125. Department of Gynecology and Obstetrics, Ludwig-Maximilians University of  
354 Munich, Munich, Germany.
- 355 126. Cancer Genetics Laboratory, Department of Genetics, University of Pretoria,  
356 Arcadia, South Africa.
- 357 127. Department of Non-Communicable Disease Epidemiology, London School of  
358 Hygiene and Tropical Medicine, London, UK.
- 359 128. Southampton Clinical Trials Unit, Faculty of Medicine, University of  
360 Southampton, Southampton, UK.
- 361 129. Cancer Sciences Academic Unit, Faculty of Medicine, University of  
362 Southampton, Southampton, UK.
- 363 130. Department of Biomedical Sciences, Faculty of Science and Technology,  
364 University of Westminster, London, UK.
- 365 131. Institute of Human Genetics, University of Münster, Münster, Germany.
- 366 132. Oncogenetics Team, The Institute of Cancer Research and Royal Marsden  
367 NHS Foundation Trust, London, UK.
- 368 133. Department of Clinical Genetics, Lund University Hospital, Lund, Sweden.
- 369 134. Department of Oncology, Rigshospitalet, Copenhagen University Hospital,  
370 Copenhagen, Denmark.
- 371 135. Institute of Human Genetics, University Hospital Erlangen, Friedrich-  
372 Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center  
373 Erlangen-EMN, Erlangen, Germany.
- 374 136. Channing Division of Network Medicine, Department of Medicine, Brigham  
375 and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- 376 137. Department of Epidemiology, Harvard T.H. Chan School of Public Health,  
377 Boston, MA, USA.



378 138. Institute for Medical Informatics, Statistics and Epidemiology, University of  
 379 Leipzig, Leipzig, Germany.  
 380 139. LIFE - Leipzig Research Centre for Civilization Diseases, University of  
 381 Leipzig, Leipzig, Germany  
 382 140. Genetics Department, Dijon University Hospital, Dijon, France  
 383 141. Oncogenetics, Centre Georges-François Leclerc, Dijon, France.  
 384 142. David Geffen School of Medicine, Department of Medicine Division of  
 385 Hematology and Oncology, University of California at Los Angeles, Los  
 386 Angeles, CA, USA.  
 387 143. Institute of Medical Genetics and Applied Genomics, University of Tuebingen,  
 388 Germany.  
 389 144. Usher Institute of Population Health Sciences and Informatics, The University  
 390 of Edinburgh Medical School, Edinburgh, UK.  
 391 145. Institute for Medical Biometrics and Epidemiology, University Medical Center  
 392 Hamburg-Eppendorf, Hamburg, Germany.  
 393 146. Department of Cancer Epidemiology, Clinical Cancer Registry, University  
 394 Medical Center Hamburg-Eppendorf, Hamburg, Germany.  
 395 147. Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer  
 396 Research, London, UK.  
 397 148. Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen  
 398 University Hospital, Herlev, Denmark.  
 399 149. Program in Cancer Genetics, Departments of Human Genetics and Oncology,  
 400 McGill University, Montreal, Quebec, Canada.  
 401 150. The Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics,  
 402 Chaim Sheba Medical Center, Ramat Gan, Israel.  
 403 151. Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.  
 404 152. School of Public Health, Curtin University, Perth, Australia.  
 405 153. Clinical Cancer Genetics Laboratory, Memorial Sloane Kettering Cancer  
 406 Center, New York, NY, USA.  
 407 154. UCLA Schools of Medicine and Public Health, Division of Cancer Prevention  
 408 & Control Research, Jonsson Comprehensive Cancer Center, Los Angeles,  
 409 CA, USA.  
 410 155. Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston,  
 411 MA, USA.  
 412 156. Centre of Familial Breast and Ovarian Cancer, Department of Medical  
 413 Genetics, Institute of Human Genetics, University Würzburg, Würzburg,  
 414 Germany.  
 415 157. Institut Curie, Department of Tumour Biology, Paris, France; Institut Curie,  
 416 INSERM U830, Paris, France.  
 417 158. Université Paris Descartes, Sorbonne Paris Cité, France.  
 418 159. Department of Medical Oncology, University Hospital of Heraklion, Heraklion,  
 419 Greece.  
 420 160. Department of Clinical Genetics, Rigshospitalet 4062, København Ø,  
 421 Denmark.  
 422 161. Department of Pathology and Laboratory Medicine, University of Kansas  
 423 Medical Center, Kansas City, KS, USA.  
 424 162. Department of Medicine, McGill University, Montreal, Canada.  
 425 163. Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University,  
 426 Montreal, Canada.

- 427 164. Department of Dermatology, Huntsman Cancer Institute, University of Utah  
428 School of Medicine, Salt Lake City, UT, USA.
- 429 165. Department of Obstetrics and Gynecology, The Ohio State University James  
430 Comprehensive Cancer Center, Columbus, OH, USA.
- 431 166. Clinical Genetics Branch, DCEG, NCI, NIH, Bethesda, MD, USA.
- 432 167. Department of Surgery, Oulu University Hospital, University of Oulu, Oulu,  
433 Finland.
- 434 168. Department of Genetics and Pathology, Pomeranian Medical University,  
435 Szczecin, Poland.
- 436 169. Centre de Recherche du Centre Hospitalier de Université de Montréal  
437 (CHUM), Montréal, Québec, Canada.
- 438 170. Department of OB/GYN and Comprehensive Cancer Centre, Medical  
439 University of Vienna, Vienna, Austria.
- 440 171. Center for Familial Breast and Ovarian Cancer, University Hospital of  
441 Cologne, Cologne, Germany.
- 442 172. Center for Integrated Oncology (CIO), University Hospital of Cologne,  
443 Cologne, Germany.
- 444 173. Center for Molecular Medicine Cologne (CMMC), University of Cologne,  
445 Cologne, Germany.
- 446 174. Department of Preventive Medicine, Keck School of Medicine, University of  
447 Southern California, Los Angeles, CA, USA.
- 448 175. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- 449 176. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
- 450 177. Molecular Genetics of Breast Cancer, German Cancer Research Center  
451 (DKFZ), Heidelberg, Germany.
- 452 178. Department of Biostatistics & Epidemiology, University of Massachusetts,  
453 Amherst, Amherst, MA, USA.
- 454 179. Center for Genomic Medicine, Rigshospitalet, Copenhagen University  
455 Hospital, Copenhagen, Denmark.
- 456 180. Translational Cancer Research Area, University of Eastern Finland, Kuopio,  
457 Finland.
- 458 181. Institute of Clinical Medicine, Pathology and Forensic Medicine, University of  
459 Eastern Finland, Kuopio, Finland.
- 460 182. Imaging Center, Department of Clinical Pathology, Kuopio University Hospital,  
461 Kuopio, Finland.
- 462 183. The Hereditary Breast and Ovarian Cancer Research Group Netherlands  
463 (HEBON), Coordinating center: Netherlands Cancer Institute, Amsterdam, The  
464 Netherlands.
- 465 184. Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals  
466 NHS Trust, Newcastle upon Tyne, UK.
- 467 185. School of Population Health, University of Western Australia, Perth, Australia.
- 468 186. Cancer Genomics Research Laboratory (CGR), Division of Cancer  
469 Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
- 470 187. Medical Genetics Unit, St George's, University of London, UK.
- 471 188. Family Cancer Clinic, The Netherlands Cancer Institute - Antoni van  
472 Leeuwenhoek hospital, Amsterdam, The Netherlands.
- 473 189. Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer  
474 Institute, Rotterdam, The Netherlands.
- 475 190. Center for Medical Genetics, NorthShore University HealthSystem, Evanston,  
476 IL, USA.

477 191. Pritzker School of Medicine, University of Chicago, Evanston, IL, USA.  
 478 192. N.N. Petrov Institute of Oncology, St.-Petersburg, Russia.  
 479 193. Lombardi Comprehensive Cancer Center, Georgetown University,  
 480 Washington, DC, USA.  
 481 194. Division of Epidemiology, Center for Public Health Sciences, National Cancer  
 482 Center, Tokyo, Japan.  
 483 195. Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, UK.  
 484 196. Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne,  
 485 Australia.  
 486 197. State Research Institute Centre for Innovative medicine, Vilnius, Lithuania.  
 487 198. Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany.  
 488 199. Department of Clinical Genetics, Aarhus University Hospital, Aarhus N,  
 489 Denmark.  
 490 200. Department of Epidemiology, Cancer Prevention Institute of California,  
 491 Fremont, CA, USA.  
 492 201. Departments of Health Research and Policy and Biomedical Data Sciences,  
 493 Stanford University School of Medicine, Stanford, CA, USA.  
 494 202. Division of Genetics and Epidemiology, The Institute of Cancer Research,  
 495 London, UK.  
 496 203. Department of Oncology, Oulu University Hospital, University of Oulu, Oulu,  
 497 Finland.  
 498 204. Department of Preventive Medicine, Seoul National University College of  
 499 Medicine, Seoul, Korea.  
 500 205. Department of Biomedical Sciences, Seoul National University College of  
 501 Medicine, Seoul, Korea.  
 502 206. Cancer Research Institute, Seoul National University, Seoul, Korea.  
 503 207. Department of Gynecology and Obstetrics, University Hospital Carl Gustav  
 504 Carus, TU Dresden, Dresden, Germany.  
 505 208. School of Medicine, National University of Ireland, Galway, Ireland.  
 506 209. Department of Human Genetics, Radboud University Nijmegen Medical  
 507 Centre, Nijmegen, The Netherlands.  
 508 210. Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven  
 509 Cancer Institute, University Hospitals Leuven, Leuven, Belgium.  
 510 211. Department of Obstetrics and Gynecology, Helsinki University Hospital,  
 511 University of Helsinki, Helsinki, Finland.  
 512 212. Department of Genetics and Fundamental Medicine, Bashkir State University,  
 513 Ufa, Russia.  
 514 213. Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research  
 515 Institute of Mount Sinai Hospital, Toronto, Canada.  
 516 214. Division of Epidemiology, Dalla Lana School of Public Health, University of  
 517 Toronto, Toronto, Canada.  
 518 215. Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific  
 519 Research "Demokritos", Athens, Greece.  
 520 216. Department of Clinical Molecular Biology, Oslo University Hospital, University  
 521 of Oslo, Oslo, Norway.  
 522 217. Department of Clinical Genetics, Odense University Hospital, Odense C,  
 523 Denmark.  
 524 218. Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong.  
 525 219. Department of Surgery, The University of Hong Kong, Hong Kong.  
 526 220. Department of Surgery, Hong Kong Sanatorium and Hospital, Hong Kong.

527 221. Department of Pathology, University Hospital of Region Zealand, division  
 528 Slagelse, Slagelse, Denmark.  
 529 222. Genetic Medicine, Manchester Academic Health Sciences Centre, Central  
 530 Manchester University Hospitals NHS Foundation Trust, Manchester, UK.  
 531 223. Clalit National Cancer Control Center, Haifa, Israel.  
 532 224. Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon,  
 533 France.  
 534 225. Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL (Bellvitge  
 535 Biomedical Research Institute), Catalan Institute of Oncology, Barcelona,  
 536 Spain.  
 537 226. University of Hawaii Cancer Center, Honolulu, HI, USA.  
 538 227. Department of Surgery, University of Ulsan College of Medicine and Asan  
 539 Medical Center, Seoul, Korea.  
 540 228. Department of Surgery, Soonchunhyang University and Hospital, Seoul,  
 541 Korea.  
 542 229. Institut Curie, Paris, France.  
 543 230. PSL Research University, Paris, France.  
 544 231. Inserm, U900, Paris, France.  
 545 232. Mines Paris Tech, Fontainebleau, France.  
 546 233. Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA.  
 547 234. Clinical Genetics Research Laboratory, Dept. of Medicine, Memorial Sloan  
 548 Kettering Cancer Center, New York, NY, USA.  
 549 235. Department of Molecular Medicine and Surgery, Karolinska Institutet,  
 550 Stockholm, Sweden.  
 551 236. Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie  
 552 Memorial Cancer Center & Institute of Oncology, Warsaw, Poland.  
 553 237. German Breast Group, Neu Isenburg, Germany.  
 554 238. Research Centre for Genetic Engineering and Biotechnology "Georgi D.  
 555 Efremov" , Macedonian Academy of Sciences and Arts, Skopje, Republic of  
 556 Macedonia.  
 557 239. Department of Medicine, Brigham and Women's Hospital, Harvard Medical  
 558 School, Boston, MA, USA.  
 559 240. Department of Oncology - Pathology, Karolinska Institutet, Stockholm,  
 560 Sweden.  
 561 241. Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.  
 562 242. Department of Family Medicine and Public Health, University of California San  
 563 Diego, La Jolla, CA, USA.  
 564 243. Division of Molecular Medicine, Aichi Cancer Center Research Institute,  
 565 Nagoya, Japan.  
 566 244. Department of Epidemiology, Nagoya University Graduate School of  
 567 Medicine, Nagoya, Japan.  
 568 245. Lyon Neuroscience Research Center - CRNL, INSERM U1028, CNRS  
 569 UMR5292, University of Lyon, Lyon, France.  
 570 246. Anatomical Pathology, The Alfred Hospital, Melbourne, Australia.  
 571 247. Department of Clinical Genetics, VU University Medical Centre, Amsterdam,  
 572 the Netherlands.  
 573 248. Servicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain.  
 574 249. Saw Swee Hock School of Public Health, National University of Singapore,  
 575 Singapore, Singapore.

576 250. NRG Oncology, Statistics and Data Management Center, Roswell Park  
577 Cancer Institute, Buffalo, NY, USA.

578 251. Institute of Population Health, University of Manchester, Manchester, UK.

579 252. Division of Health Sciences, Warwick Medical School, Warwick University,  
580 Coventry, UK.

581 253. Department of Laboratory Medicine and Pathobiology, University of Toronto,  
582 Toronto, Canada.

583 254. Laboratory Medicine Program, University Health Network, Toronto, Canada.

584 255. Université Paris Sorbonne Cité, INSERM UMR-S1147, Paris, France.

585 256. Department of Gynecology and Obstetrics, University Hospital Düsseldorf,  
586 Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.

587 257. 513 Parnassus Ave., HSE 901E, San Francisco, CA, USA.

588 258. Center for Clinical Cancer Genetics and Global Health, The University of  
589 Chicago, Chicago, IL, USA.

590 259. West Midlands Regional Genetics Service, Birmingham Women's Hospital  
591 Healthcare NHS Trust, Edgbaston, Birmingham, UK.

592 260. Department of Genetics, University Medical Center, Groningen University,  
593 Groningen, The Netherlands.

594 261. University of New Mexico Health Sciences Center, University of New Mexico,  
595 Albuquerque, NM, USA.

596 262. Unit of Medical Genetics, Department of Biomedical, Experimental and  
597 Clinical Sciences, University of Florence, Florence, Italy.

598 263. Department of Immunology, Genetics and Pathology, Uppsala  
599 University, Uppsala, Sweden.

600 264. The Curtin UWA Centre for Genetic Origins of Health and Disease, Curtin  
601 University and University of Western Australia, Perth, Australia.

602 265. Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University  
603 Hospital, Aalborg, Denmark.

604 266. Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.

605 267. Servicio de Cirugía General y Especialidades, Hospital Monte Naranco,  
606 Oviedo, Spain.

607 268. IFOM, The FIRC (Italian Foundation for Cancer Research) Institute of  
608 Molecular Oncology, Milan, Italy.

609 269. Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.

610 270. South East of Scotland Regional Genetics Service, Western General Hospital,  
611 Edinburgh, UK.

612 271. ProCURE, Catalan Institute of Oncology, IDIBELL (Bellvitge Biomedical  
613 Research Institute), Barcelona, Spain.

614 272. Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational  
615 Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.

616 273. Laboratory of Cancer Genetics and Tumor Biology, Northern Finland  
617 Laboratory Centre Oulu, Oulu, Finland.

618 274. Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of  
619 Preventive and Predictive Medicine, Fondazione IRCCS (Istituto Di Ricovero  
620 e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), Milan, Italy.

621 275. Section of Cancer Genetics, The Institute of Cancer Research, London, UK.

622 276. Department of Clinical Genetics, Karolinska University Hospital, Stockholm,  
623 Sweden.

624 277. Carmel Medical Center and B. Rappaport Faculty Of Medicine-Technion,  
625 Haifa, Israel.

- 626 278. Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA  
627 USA.
- 628 279. Division of Gynecologic Oncology, NorthShore University HealthSystem,  
629 University of Chicago, Evanston, IL, USA.
- 630 280. Medical Oncology Department, Hospital Universitario Puerta de Hierro,  
631 Madrid, Spain.
- 632 281. Department of Epidemiology. Netherlands Cancer Institute, Amsterdam, The  
633 Netherlands.
- 634 282. Institute of Pathology, Staedisches Klinikum Karlsruhe, Karlsruhe, Germany.
- 635 283. Hereditary Cancer Clinic, University Hospital of Heraklion, Heraklion, Greece.
- 636 284. Department of Pathology, The Netherlands Cancer Institute - Antoni van  
637 Leeuwenhoek hospital, Amsterdam, The Netherlands.
- 638 285. Epidemiology Branch, National Institute of Environmental Health Sciences,  
639 NIH, Research Triangle Park, NC, USA.
- 640 286. National Cancer Institute, Bangkok, Thailand.
- 641 287. Research Oncology, Guy's Hospital, King's College London, London, UK.
- 642 288. Division of Molecular Medicine, Pathology North, John Hunter Hospital,  
643 Newcastle, Australia.
- 644 289. Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy,  
645 Faculty of Health, University of Newcastle, Callaghan, Australia.
- 646 290. Clinical Cancer Genetics Program, Division of Human Genetics, Department  
647 of Internal Medicine, The Comprehensive Cancer Center, The Ohio State  
648 University, Columbus, USA.
- 649 291. Department of Medicine, Kansas Medical Center, Kansas City, KS, USA.
- 650 292. School of Public Health, China Medical University, Taichung, Taiwan.
- 651 293. Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei,  
652 Taiwan.
- 653 294. North East Thames Regional Genetics Service, Great Ormond Street Hospital  
654 for Children NHS Trust, London, UK.
- 655 295. National Center for Tumor Diseases, University of Heidelberg, Heidelberg,  
656 Germany.
- 657 296. Department of Pathology, The University of Melbourne, Melbourne, Australia.
- 658 297. Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
- 659 298. School of Population and Public Health, University of British Columbia,  
660 Vancouver, BC, Canada.
- 661 299. Saarland Cancer Registry, Saarbrücken, Germany.
- 662 300. Institute of Human Genetics, University Hospital Heidelberg, Heidelberg,  
663 Germany.
- 664 301. Division of Breast Cancer Research, The Institute of Cancer Research,  
665 London, UK.
- 666 302. National Human Genome Research Institute ,National Institutes of Health,  
667 Bethesda, MD, USA.
- 668 303. Dept of OB/GYN and Comprehensive Cancer Center, Medical University of  
669 Vienna, Vienna, Austria.
- 670 304. Epigenetic and Stem Cell Biology Laboratory, National Institute of  
671 Environmental Health Sciences, NIH, Research Triangle Park, NC, USA.
- 672 305. Molecular Genetics Laboratory, Clinical Genetics Service, Cruces University  
673 Hospital. BioCruces Health Research Institute, Barakaldo, Spain.
- 674 306. Cancer Center, Kuopio University Hospital, Kuopio, Finland.

- 675 307. Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio,  
676 Finland.
- 677 308. Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia.
- 678 309. Breast Cancer Research Unit, Cancer Research Institute, University Malaya  
679 Medical Centre, Kuala Lumpur, Malaysia.
- 680 310. Department of Epidemiology, Mailman School of Public Health, Columbia  
681 University, New York, NY, USA.
- 682 311. Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL (Bellvitge  
683 Biomedical Research Institute), Catalan Institute of Oncology, Barcelona,  
684 Spain.
- 685 312. Magee-Womens Hospital, University of Pittsburgh School of Medicine,  
686 Pittsburgh, PA, USA.
- 687 313. Ospedale di Circolo ASST Settelaghi, Varese, Italy.
- 688 314. Latvian Biomedical Research and Study Centre, Riga, Latvia.
- 689 315. Department of Medical Genetics, Addenbrooke's Treatment Centre,  
690 Addenbrooke's Hospital, Cambridge, UK.
- 691 316. Department of Molecular Virology, Immunology and Medical Genetics,  
692 Comprehensive Cancer Center, The Ohio State University, Columbus, OH,  
693 USA.
- 694 317. Department of Surgery, Leiden University Medical Center, Leiden, The  
695 Netherlands.
- 696 318. Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical  
697 Research Centre, University of Oxford, Oxford, UK.
- 698 319. Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota,  
699 Colombia.
- 700 320. Hereditary Cancer Clinic, Department of Medical Oncology, Prince of Wales  
701 Hospital, Randwick, Australia.
- 702 321. Department of Medical Oncology, Beth Israel Deaconess Medical Center, MA,  
703 USA.
- 704 322. Frauenklinik der Stadtklinik Baden-Baden, Baden-Baden, Germany.
- 705 323. Department of Clinical Genetics, Leiden University Medical Center, Leiden,  
706 The Netherlands.
- 707 324. Department of Clinical Genetics, Erasmus University Medical Center,  
708 Rotterdam, The Netherlands.
- 709 325. Unit of Hereditary Cancer, Department of Epidemiology, Prevention and  
710 Special Functions, IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico )  
711 AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, largo  
712 Rosanna Benzi 10, 16132 Genoa, Italy.
- 713 326. Institute of Human Genetics, Campus Virchow Klinikum, Charite Berlin,  
714 Germany.
- 715 327. Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde  
716 (SERGAS), Instituto de Investigaciones Sanitarias (IDIS), Santiago de  
717 Compostela, Spain.
- 718 328. Grupo de Medicina Xenómica, Centro de Investigación Biomédica en Red de  
719 Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela  
720 (USC), Santiago de Compostela, Spain.
- 721 329. Unit of Functional onco-genomics and genetics, CRO Aviano, National  
722 Cancer Institute, Via Franco Gallini 2, 33081 Aviano (PN), Italy.
- 723 330. Oxford Regional Genetics Service, Churchill Hospital, Oxford, UK.

- 724 331. Department of Computational Biology, St. Jude Children's Research Hospital,  
725 Memphis, TN, USA.
- 726 332. Biostatistics and Computational Biology Branch, National Institute of  
727 Environmental Health Sciences, NIH, Research Triangle Park, NC, USA.
- 728 333. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston,  
729 MA, USA.
- 730 334. Department of Medicine, Institute for Human Genetics, UCSF Helen Diller  
731 Family Comprehensive Cancer Center, University of California San Francisco,  
732 San Francisco, CA, USA.
- 733 335. Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
- 734 336. Department of Obstetrics and Gynaecology, University of Melbourne and the  
735 Royal Women's Hospital, Melbourne, Australia.
- 736 337. Clinical Genetics Research Lab, Department of Cancer Biology and Genetics,  
737 Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
- 738 338. Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering  
739 Cancer Center, New York, NY, USA.
- 740 339. Department of Molecular Medicine, University La Sapienza, c/oPoliclinico  
741 Umberto I, Rome, Italy.
- 742 340. Division of Gynaecology and Obstetrics, Technische Universität München,  
743 Munich, Germany.
- 744 341. Division of Psychosocial Research and Epidemiology, The Netherlands  
745 Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The  
746 Netherlands.

747

748



Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWASs) of predominantly estrogen receptor (ER)-positive disease. We conducted a GWAS using 21,468 ER-negative cases and 100,594 controls combined with 18,908 *BRCA1* mutation carriers (9,414 with breast cancer), all of European origin. We identified independent associations at  $P < 5 \times 10^{-8}$  with 10 variants at nine novel loci. At  $P < 0.05$ , we replicated associations with 10 of 11 variants previously reported in ER-negative or *BRCA1* mutation carrier GWASs, and confirmed ER-negative disease associations for 105 susceptibility variants identified by other breast cancer GWASs. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for *BRCA1* carriers. These findings will lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.

GWASs have identified 107 single nucleotide polymorphisms (SNPs) that are independently associated with breast cancer risk<sup>1-31</sup>. Association studies focused on ER-negative disease, or *BRCA1* mutation carriers, who are more likely to develop ER-negative disease (70-80% of cases)<sup>32</sup>, have identified 11 of these SNPs<sup>2,8,11,18,28,29</sup>. We aimed to discover additional ER-negative breast cancer susceptibility variants by performing a GWAS in women of European origin.

New genotyping data were generated for 9,655 ER-negative cases and 45,494 controls from 68 Breast Cancer Association Consortium (BCAC) studies and 15,566 *BRCA1* mutation carriers (7,784 with breast cancer) from 58 Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) studies (Supplementary Tables 1 and 2) using the Illumina OncoArray beadchip, a 570K SNP custom array with genome-wide coverage<sup>33</sup>. Imputation was used to derive estimated genotypes for ~21M SNPs, using the 1000 Genomes Project (Phase 3) as reference; ~11.5M of those with imputation  $r^2 > 0.3$  and minor allele frequency (MAF)  $> 0.005$  were included in further analyses. For BCAC data, we estimated per-allele odds ratios (ORs) using logistic regression, adjusting for country and principal components. For CIMBA data, we estimated per-allele hazard ratios (HR) using a retrospective cohort analysis framework, modelling time to breast cancer and stratifying on country, Ashkenazi Jewish origin and birth cohort (see Online Methods). These analyses were also applied to an independent set of previously generated data from other genome-wide genotyping of additional European participants in 44 BCAC studies (11,813 ER-negative cases and 55,100 controls) and 54 CIMBA studies (3,342 *BRCA1* mutation carriers, 1,630 with breast cancer) (Supplementary Tables 1 and 2). Fixed-effects meta-analysis was used to combine results across genotyping initiatives within consortia and, assuming that the OR and HR estimates approximate the same underlying relative risk, across consortia.

Results from the combined meta-analysis are summarised in Supplementary Figure 1. There was minimal inflation of test statistics ( $\lambda_{1000} = 1.004$ ; Supplementary Figure 2). We identified 10 variants at nine novel loci that were independently associated with risk of ER-negative breast cancer at  $P < 5 \times 10^{-8}$  (Table 1; Supplementary Table 3; Supplementary Figures 3-10). Two independent signals were observed within 12kb at 11q22.3, for rs74911261 (MAF=0.02) and rs11374964 (MAF=0.42); OR estimates and statistical significance were largely unchanged when

each variant was adjusted for the other (Supplementary Table 4). The association with 8p23.3-rs66823261 was not observed for *BRCA1* mutation carriers ( $P=0.32$ ,  $P$ -heterogeneity=0.030).

For each of these 10 novel signals, we identified candidate causal SNPs analytically (see Online Methods) and combined multiple sources of *in silico* functional annotation from public databases to identify likely functional variants and target genes. Results are summarised in Supplementary Table 5 (including UCSC Genome Browser links; see also Supplementary Note 1), Figure 1 and Supplementary Figures 3-10 (data sources in Supplementary Table 6). Many candidate causal SNPs lie in predicted regulatory regions and are associated with expression of nearby genes in blood or other tissues. At 2p23, the predicted target genes include *ADCY3* and *NCOA1* (Supplementary Figure 3). At 6q23.1 (Supplementary Figure 4), the most plausible target gene is *L3MBTL3*<sup>34</sup>. A predicted target at 8q24.13 is *FBXO32*, which is expressed in ER-negative HMECs but not ER-positive MCF7 breast cancer cells (Supplementary Figure 6) and has a known role in cancer cachexia<sup>35</sup>. At 11q22.3 (Figure 1), a predicted target gene of common risk-associated variants is *NPAT*<sup>36</sup>. The rarer SNPs underlying the other 11q22.3 signal are predicted to target *ATM*, a known breast cancer susceptibility gene<sup>37</sup>. Three rare coding variants ( $MAF \leq 0.03$ ) in *ATM*, *NPAT* and *KDELC2*, are also among the candidate causal SNPs at this locus. At 16p13, predicted target genes include *ADCY9* and *CREBBP* (Supplementary Figure 7). At 19q12 (Supplementary Figure 10), a potential target gene encodes cyclin E1 which is involved in cell cycle control and phosphorylation of *NPAT*<sup>38</sup>.

Expression QTL associations were assessed between each candidate causal variant and genes within 1Mb using 79 ER-negative breast tumours from TCGA and 135 normal breast tissue samples from METABRIC<sup>39-41</sup>. The strongest associations identified were 6q23.1-rs6569648-*L3MBTL3* ( $P=4.3 \times 10^{-6}$ ) and 18q12.1-rs12965632-*CDH2* ( $P=1.0 \times 10^{-4}$ ), both in METABRIC (Supplementary Table 5). SNP rs6569648 was the top *cis*-eQTL (of all imputed variants within 1 Mb) for *L3MBTL3* while the *p*-value for the rs12965632-*CDH2* eQTL was within two orders of magnitude of the top *cis*-eQTLs for this gene (Supplementary Figures 11-12).

For 10 of the 11 variants previously identified through GWASs of ER-negative disease or overall disease in *BRCA1* mutation carriers<sup>2,8,11,17,18,29,30</sup>, or reported as more strongly associated with ER-negative breast cancer<sup>28</sup>, associations with ER-negative disease were replicated ( $P < 0.05$ ) using OncoArray data from BCAC, which does not overlap with any of the discovery studies (Table 2). Effect sizes were generally similar to those originally reported. Using all available CIMBA data, six of these 11 variants were associated with breast cancer risk ( $P < 0.05$ ) for *BRCA1* mutation carriers (Table 2). No evidence of association was observed for 20q11-rs2284378<sup>11</sup> in either BCAC or CIMBA ( $P \geq 0.46$ ).

Based on estimated ORs using BCAC data for all cases with known ER status (16,988 ER-negative; 65,275 ER-positive), all 10 new and 10 previously reported and replicated ER-negative disease susceptibility SNPs were more strongly associated with risk of ER-negative than ER-positive subtype ( $P$ -heterogeneity  $< 0.05$ , except for novel hit 19p13.2-rs322144; Supplementary Table 7). Two variants (1q32.1-rs4245739 and 19p13.11-rs67397200) were not associated with ER-positive disease. For four variants (11q22.3-rs11374964, 11q22.3-rs74911261, 1q32.1-

rs6678914 and 2p23.2-rs4577244), the risk-associated allele for ER-negative disease was associated with reduced risk of ER-positive disease ( $P<0.05$ ).

For these 20 ER-negative breast cancer susceptibility SNPs, we also assessed associations by triple-negative (TN) status (negative for ER, progesterone receptor and HER2; Table 3), tumour grade (Table 4) and age at diagnosis (Supplementary Table 8) using BCAC data only. Five, including the novel susceptibility variants 11q22.3-rs11374964 and 11q22.3-rs74911261, were more strongly associated with risk of both TN and higher-grade disease ( $P<0.05$ ), although after adjustment for TN status, heterogeneity by grade was observed only for 11q22.3-rs74911261 and 1q32.1-rs4245739 ( $P<0.05$ ). For 2p23.3-rs4577244, heterogeneity was observed for grade only, while 6q25.2-rs2747652 was more strongly associated with risk of other (non-TN) ER-negative breast cancer subtypes ( $P<0.05$ ). At younger ages, associations appeared to be stronger for two variants (5p15.33-rs10069690 and 19p13.11-rs67397200), and weaker for one (6q25.2-rs2747652) ( $P<0.05$ ).

Elsewhere we report 65 novel susceptibility loci for overall breast cancer<sup>42</sup>. Three of these overlap within 500kb with the novel ER-negative disease-associated loci reported here (variants 2p23.3-rs200648189, 6q23.1-rs6569648 and 8q24.13-rs17350191). We assessed associations with risk of ER-negative disease, and with risk of overall breast cancer for *BRCA1* mutation carriers, for SNPs at the remaining 62 loci, as well as for the 96 previously reported breast cancer susceptibility variants that were not ER-negative specific. Of these 158 SNPs, 105 were associated ( $P<0.05$ ) with risk of ER-negative breast cancer, and 24 with risk for *BRCA1* mutation carriers (Supplementary Tables 9-10). Results for *BRCA2* mutation carriers are presented in Supplementary Table 11.

Pathway analysis based on mapping each SNP to the nearest gene was performed using summary association statistics from the meta-analysis of BCAC and CIMBA data combined (see Online Methods). This identified several pathways implicated in ER-negative disease (enrichment score [ES] $>0.4086$ ; Supplementary Figure 13; Supplementary Tables 12-13), including a subset that was not enriched in susceptibility to ER-positive disease (ES $<0$ ; Supplementary Table 14). One of the latter subsets was the adenylate cyclase (AC) activating pathway (ES=0.62; Supplementary Figure 14). Two of the predicted target genes for the 10 novel ER-negative breast cancer susceptibility variants, based on the eQTL analysis (Supplementary Table 5), *ADCY3* ( $P[\text{TCGA}]=6.7\times10^{-3}$ ) and *ADCY9* ( $P[\text{METABRIC}]=1.3\times10^{-4}$ ), are part of this pathway, and their association signals were critical to the elevated ES observed (Supplementary Figure 13). *ADCY9* is stimulated by  $\beta_2$  adrenergic receptor ( $\beta_2\text{AR}$ ) signalling<sup>43</sup> in ER-negative breast cancer<sup>44</sup>, which in turn drives AC-cAMP signalling, including for example mitogenic signalling through  $\beta$ -arrestin-Src-ERK<sup>45</sup>.

To further explore the functional properties of the genome that contribute to ER-negative breast cancer heritability, we conducted a partitioned heritability analysis using linkage disequilibrium (LD) score regression<sup>46</sup>. Considering 52 “baseline” genomic features, we observed the greatest enrichment for super-enhancers (2.5-fold,  $p=2\times10^{-7}$ ) and the H3K4me3 histone mark (2.4-fold,  $p=0.0005$ ), with 33% depletion ( $p=0.0002$ ) observed for repressed regions (Supplementary Table 15). No differences in enrichment for these features were observed between susceptibility to ER-negative and ER-positive breast cancer, but baseline genomic features are not

specific to cell type<sup>46</sup>. The estimated correlation between ER-negative and ER-positive breast cancer based on ~1M common genetic variants<sup>47</sup> was 0.60 (standard error [SE], 0.03) indicating that, although these two breast cancer subtypes have a shared genetic component, a substantial proportion is distinct. The estimated correlation between ER-negative disease in the general population and overall breast cancer for *BRCA1* mutation carriers was 0.72 (SE, 0.11).

In summary, in this study of women of European origin, we have identified 10 novel susceptibility variants for ER-negative breast cancer and replicated associations with ER-negative disease for 10 SNPs identified by previous GWASs. Most of these were not associated, or more weakly associated, with ER-positive disease, consistent with the findings from pathway and partitioned heritability analyses showing that ER-negative breast cancer has a partly distinct genetic aetiology. We also confirmed associations with ER-negative disease for a further 105 susceptibility SNPs. Together, these 125 variants explain ~14% of an assumed 2-fold increased risk of developing ER-negative disease for the first degree female relatives of women affected with this subtype (the newly identified SNPs explain ~1.5%); Supplementary Table 16) and ~40% of the estimated familial risk that is attributable to all variants imputable from the Oncoarray (see Online Methods). We have also identified nine novel breast cancer susceptibility variants for *BRCA1* mutation carriers and confirmed associations for a further 30 previously reported SNPs; these 39 variants explain ~8% of the variance in polygenic risk for carriers of these mutations (Supplementary Table 17). However, the lower number of *BRCA1* risk-associated variants may merely be a consequence of the smaller sample size, since the genetic correlation with ER-negative breast cancer is high. These findings will inform improved risk prediction, both for the general population and for *BRCA1* mutation carriers<sup>29,48,49</sup>. Further investigation is required for other populations of non-European origin. Fine-mapping and functional studies should lead to a better understanding of the biological basis of ER-negative breast cancer, and perhaps inform the design of more effective preventive interventions, early detection and treatments for this disease.

## References

1. Ahmed, S. *et al.* Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nat Genet* **41**, 585-90 (2009).
2. Antoniou, A.C. *et al.* A locus on 19p13 modifies risk of breast cancer in *BRCA1* mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet* **42**, 885-92 (2010).
3. Cai, Q. *et al.* Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. *Hum Mol Genet* **20**, 4991-9 (2011).
4. Cox, A. *et al.* A common coding variant in *CASP8* is associated with breast cancer risk. *Nat Genet* **39**, 352-8 (2007).
5. Easton, D.F. *et al.* Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* **447**, 1087-93 (2007).
6. Fletcher, O. *et al.* Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. *J Natl Cancer Inst* **103**, 425-35 (2011).
7. Ghoussaini, M. *et al.* Genome-wide association analysis identifies three new breast cancer susceptibility loci. *Nat Genet* **44**, 312-8 (2012).

- 940 8. Haiman, C.A. *et al.* A common variant at the TERT-CLPTM1L locus is associated  
941 with estrogen receptor-negative breast cancer. *Nat Genet* **43**, 1210-4 (2011).
- 942 9. Hein, R. *et al.* Comparison of 6q25 breast cancer hits from Asian and European  
943 Genome Wide Association Studies in the Breast Cancer Association Consortium  
944 (BCAC). *PLoS One* **7**, e42380 (2012).
- 945 10. Hunter, D.J. *et al.* A genome-wide association study identifies alleles in FGFR2  
946 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet* **39**, 870-4  
947 (2007).
- 948 11. Siddiq, A. *et al.* A meta-analysis of genome-wide association studies of breast cancer  
949 identifies two novel susceptibility loci at 6q14 and 20q11. *Hum Mol Genet* **21**, 5373-  
950 84 (2012).
- 951 12. Stacey, S.N. *et al.* Common variants on chromosomes 2q35 and 16q12 confer  
952 susceptibility to estrogen receptor-positive breast cancer. *Nat Genet* **39**, 865-9  
953 (2007).
- 954 13. Stacey, S.N. *et al.* Common variants on chromosome 5p12 confer susceptibility to  
955 estrogen receptor-positive breast cancer. *Nat Genet* **40**, 703-6 (2008).
- 956 14. Thomas, G. *et al.* A multistage genome-wide association study in breast cancer  
957 identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). *Nat Genet* **41**, 579-  
958 84 (2009).
- 959 15. Turnbull, C. *et al.* Genome-wide association study identifies five new breast cancer  
960 susceptibility loci. *Nat Genet* **42**, 504-7 (2010).
- 961 16. Zheng, W. *et al.* Genome-wide association study identifies a new breast cancer  
962 susceptibility locus at 6q25.1. *Nat Genet* **41**, 324-8 (2009).
- 963 17. Bojesen, S.E. *et al.* Multiple independent variants at the TERT locus are associated  
964 with telomere length and risks of breast and ovarian cancer. *Nat Genet* **45**, 371-84  
965 (2013).
- 966 18. Garcia-Closas, M. *et al.* Genome-wide association studies identify four ER negative-  
967 specific breast cancer risk loci. *Nat Genet* **45**, 392-8 (2013).
- 968 19. Michailidou, K. *et al.* Large-scale genotyping identifies 41 new loci associated with  
969 breast cancer risk. *Nat Genet* **45**, 353-61 (2013).
- 970 20. Cai, Q. *et al.* Genome-wide association analysis in East Asians identifies breast  
971 cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. *Nat Genet* **46**, 886-90  
972 (2014).
- 973 21. Long, J. *et al.* Genome-wide association study in east Asians identifies novel  
974 susceptibility loci for breast cancer. *PLoS Genet* **8**, e1002532 (2012).
- 975 22. Michailidou, K. *et al.* Genome-wide association analysis of more than 120,000  
976 individuals identifies 15 new susceptibility loci for breast cancer. *Nat Genet* **47**, 373-  
977 80 (2015).
- 978 23. Milne, R.L. *et al.* Common non-synonymous SNPs associated with breast cancer  
979 susceptibility: findings from the Breast Cancer Association Consortium. *Hum Mol*  
980 *Genet* **23**, 6096-111 (2014).
- 981 24. Gaudet, M.M. *et al.* Identification of a BRCA2-specific modifier locus at 6p24 related  
982 to breast cancer risk. *PLoS Genet* **9**, e1003173 (2013).
- 983 25. Meyer, K.B. *et al.* Fine-scale mapping of the FGFR2 breast cancer risk locus:  
984 putative functional variants differentially bind FOXA1 and E2F1. *Am J Hum Genet* **93**,  
985 1046-60 (2013).
- 986 26. Orr, N. *et al.* Fine-mapping identifies two additional breast cancer susceptibility loci at  
987 9q31.2. *Hum Mol Genet* **24**, 2966-84 (2015).
- 988 27. French, J.D. *et al.* Functional variants at the 11q13 risk locus for breast cancer  
989 regulate cyclin D1 expression through long-range enhancers. *Am J Hum Genet* **92**,  
990 489-503 (2013).
- 991 28. Dunning, A.M. *et al.* Breast cancer risk variants at 6q25 display different phenotype  
992 associations and regulate ESR1, RMND1 and CCDC170. *Nat Genet* (in press).
- 993 29. Couch, F.J. *et al.* Identification of four novel susceptibility loci for estrogen receptor  
994 negative breast cancer. *Nat Commun* (in press).



995 30. Lawrenson, K. *et al.* Functional Mechanisms Underlying Pleiotropic Risk Alleles At  
996 The 19p13.1 Breast-Ovarian Cancer Susceptibility Locus. *Nat Commun* (in press).  
997 31. Wyszynski, A. *et al.* An intergenic risk locus containing an enhancer deletion in 2q35  
998 modulates breast cancer risk by deregulating IGFBP5 expression. *Hum Mol Genet*  
999 (in press).  
1000 32. Mavaddat, N. *et al.* Pathology of breast and ovarian cancers among BRCA1 and  
1001 BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of  
1002 BRCA1/2 (CIMBA). *Cancer Epidemiol Biomarkers Prev* **21**, 134-47 (2012).  
1003 33. Amos, C.I. *et al.* The OncoArray Consortium: a Network for Understanding the  
1004 Genetic Architecture of Common Cancers. *Cancer Epidemiol Biomarkers Prev* (in  
1005 press).  
1006 34. James, L.I. *et al.* Small-molecule ligands of methyl-lysine binding proteins:  
1007 optimization of selectivity for L3MBTL3. *J Med Chem* **56**, 7358-71 (2013).  
1008 35. Sukari, A., Muqbil, I., Mohammad, R.M., Philip, P.A. & Azmi, A.S. F-BOX proteins in  
1009 cancer cachexia and muscle wasting: Emerging regulators and therapeutic  
1010 opportunities. *Semin Cancer Biol* **36**, 95-104 (2016).  
1011 36. Ling Zheng, L. *et al.* Interaction of Heat Shock Protein Cpn10 with the Cyclin E/Cdk2  
1012 Substrate Nuclear Protein Ataxia-Telangiectasia (NPAT) Is Involved in Regulating  
1013 Histone Transcription. *J Biol Chem* **290**, 29290-300 (2015).  
1014 37. Easton, D.F. *et al.* Gene-panel sequencing and the prediction of breast-cancer risk. *N*  
1015 *Engl J Med* **372**, 2243-57 (2015).  
1016 38. Rogers, S. *et al.* Cyclin E2 is the predominant E-cyclin associated with NPAT in  
1017 breast cancer cells. *Cell Div* **10**, 1 (2015).  
1018 39. Li, Q. *et al.* Integrative eQTL-based analyses reveal the biology of breast cancer risk  
1019 loci. *Cell* **152**, 633-41 (2013).  
1020 40. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast  
1021 tumours. *Nature* **490**, 61-70 (2012).  
1022 41. Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours  
1023 reveals novel subgroups. *Nature* **486**, 346-52 (2012).  
1024 42. Michailidou, K. *et al.* Identification of more than 70 new breast cancer susceptibility  
1025 loci for breast cancer and definition of risk-associated genomic features. *Nature*  
1026 (under review).  
1027 43. Hacker, B.M. *et al.* Cloning, chromosomal mapping, and regulatory properties of the  
1028 human type 9 adenylyl cyclase (ADCY9). *Genomics* **50**, 97-104 (1998).  
1029 44. Melhem-Bertrandt, A. *et al.* Beta-blocker use is associated with improved relapse-  
1030 free survival in patients with triple-negative breast cancer. *J Clin Oncol* **29**, 2645-52  
1031 (2011).  
1032 45. Pon, C.K., Lane, J.R., Sloan, E.K. & Halls, M.L. The beta2-adrenoceptor activates a  
1033 positive cAMP-calcium feedforward loop to drive breast cancer cell invasion. *FASEB*  
1034 *J* **30**, 1144-54 (2016).  
1035 46. Finucane, H.K. *et al.* Partitioning heritability by functional annotation using genome-  
1036 wide association summary statistics. *Nat Genet* **47**, 1228-35 (2015).  
1037 47. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and  
1038 traits. *Nat Genet* **47**, 1236-41 (2015).  
1039 48. Milne, R.L. & Antoniou, A.C. Genetic modifiers of cancer risk for BRCA1 and BRCA2  
1040 mutation carriers. *Ann Oncol* **22 Suppl 1**, i11-7 (2011).  
1041 49. Mavaddat, N. *et al.* Prediction of breast cancer risk based on profiling with common  
1042 genetic variants. *J Natl Cancer Inst* **107**(2015).  
1043 50. He, B., Chen, C., Teng, L. & Tan, K. Global view of enhancer-promoter interactome  
1044 in human cells. *Proc Natl Acad Sci U S A* **111**, E2191-9 (2014).  
1045 51. Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell* **155**,  
1046 934-47 (2013).  
1047 52. Rao, S.S. *et al.* A 3D map of the human genome at kilobase resolution reveals  
1048 principles of chromatin looping. *Cell* **159**, 1665-80 (2014).

53. Corradin, O. *et al.* Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. *Genome Res* **24**, 1-13 (2014).

## Acknowledgements

Genotyping of the OncoArray was funded by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (GPH-129344), the *Ministère de l'Économie, de la Science et de l'Innovation du Québec* through Genome Québec, the Quebec Breast Cancer Foundation for the PERSPECTIVE project, the US National Institutes of Health (NIH) [1 U19 CA 148065 for the Discovery, Biology and Risk of Inherited Variants in Breast Cancer (DRIVE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I], Cancer Research UK [C1287/A16563], Odense University Hospital Research Foundation (Denmark), the National R&D Program for Cancer Control - Ministry of Health & Welfare (Republic of Korea) [1420190], the Italian Association for Cancer Research [AIRC, IG16933], the Breast Cancer Research Foundation, the National Health and Medical Research Council (Australia) and German Cancer Aid [110837].

Genotyping of the iCOGS array was funded by the European Union [HEALTH-F2-2009-223175], Cancer Research UK [C1287/A10710, C1287/A10118, C12292/A11174], NIH grants (CA128978, CA116167, CA176785) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201) the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, the *Ministère de l'Économie, Innovation et Exportation du Québec* (#PSR-SIIRI-701), Komen Foundation for the Cure, the Breast Cancer Research Foundation and the Ovarian Cancer Research Fund.

Combining the GWAS data was supported in part by NIH Cancer Post-Cancer GWAS initiative [1 U19 CA 148065] (DRIVE, part of the GAME-ON initiative). LD score regression analysis was supported by CA194393.

BCAC is funded by Cancer Research UK [C1287/A16563] and by the European Union via its Seventh Framework Programme [HEALTH-F2-2009-223175, (COGS)] and Horizon 2020 Research & Innovation Programme [633784 (B-CAST); 634935 (BRIDGES)]. CIMBA is funded by Cancer Research UK [C12292/A20861 and C12292/A11174].

We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians and administrative staff who have enabled this work to be carried out.

For a full description of funding and acknowledgments, see Supplementary Note 2.

## Author Contributions

1092 Writing group: R.L.M., K.B.K, K.Michailidou, J.Beesley, S.Kar, S.Lindström, S.Hui.,  
 1093 G.D.B., P.D.P.P., F.J.C., D.F.E., P.K., G.CT., M.GC., M.K.S., A.C.A., J.Simard.

1094 Conceived and coordinated the synthesis of the Oncoarray: D.F.E., A.C.A., J.  
 1095 Simard, C.I.A., J.Byun, S.J.C., E.D., D.J.H., A.Lee, P.D.P.P., J.T., Z.W.

1096 OncoArray genotyping: M.A., A.C.A., S.E.B., M.K.B., F.B., G.CT., J.M.C., K.F.D.,  
 1097 D.F.E., N.Hammell, B.Hicks, K.J., C.Luccarini, L.M, J.M., E.P., J.Romm, M.K.S.,  
 1098 X.S., J.Simard., P.Soucy, D.C.T., D.V., J.Vollenweider, L.X., B.Z.

1099 Oncoarray genotype calling and quality control: X.C., J.D., E.D., D.F.E., K.B.K,  
 1100 J.Lecarpentier, A.Lee, M.Lush.

1101 Database management: D.B., M.K.B., M.L., L.McG., Q.W., R.Keeman, M.K.S.

1102 Statistical analysis: K.B.K, K.Michailidou, S.Hui, S.Kar, X.J., A.Rostamianfar,  
 1103 H.Finucane, S.Lindström, P.K., P.D.P.P., G.D.B., R.L.M., A.C.A., D.F.E.

1104 Bioinformatic analysis: J.Beesley, P.Soucy, A.Lemaçon, F.AE. A.D., J. Simard,  
 1105 G.CT.

1106 Provided DNA samples and/or phenotypic data: ABCTB.I., C.M.A., J.Adlard,  
 1107 S.Agata, S.Ahmed, J.Allen, K.A., C.B.A., I.L.A., H.AC., N.N.A., A.C.A., V.A., N.A.,  
 1108 K.J.A., B.A., P.L.A., M.G.E.M.A., J.Azzollini, J.Balmaña, M.Barile, L.Barjhoux,  
 1109 R.B.B., M.Barrdahl, D.B., C.Baynes, M.W.B., J.Beesley, J.Benitez, M.Bermisheva,  
 1110 L.Bernstein, YJ.B., K.R.B., M.J.B., C.Blomqvist, W.B., K.B., B.Boeckx, N.V.B.,  
 1111 A.Bojesen, S.E.B., M.K.B., B.Bonanni, A.Bozsik, A.R.B., J.S.B., H.Brauch,  
 1112 H.Brenner, B.BdP., C.Brewer, L.Brinton, P.B., A.BW., J.Brunet, T.B., B.Burwinkel,  
 1113 S.S.B., AL.BW., Q.C., T.Caldés, M.A.C., I.Campbell, F.C., O.C., A.Carracedo,  
 1114 B.D.C., J.E.C., L.C., V.CM., S.B.C., J.CC., S.J.C., X.C., G.CT., TYD.C., J.Chiquette,  
 1115 H.C., K.B.M.C., C.L.C., NBCS.C., T.Conner, D.M.C., J.Cook, E.CD., S.C., F.J.C.,  
 1116 I.Coupier, D.C., A.Cox, S.S.C., K.Cuk, K.Czene, M.B.D., F.D., H.D., R.D., K.D., J.D.,  
 1117 P.D., O.D., YC.D., N.D., S.M.D., C.M.D., S.D., PA.D., M.Dumont, A.M.D., L.D.,  
 1118 M.Dwek, B.D., T.D., EMBRACE, D.F.E., D.E., R.E., H.Ehrencrona, U.E., B.E.,  
 1119 A.B.E., A.H.E., C.E., M.E., L.Fachal, L.Faivre, P.A.F., U.F., J.F., D.FJ., O.F.,  
 1120 H.Flyger, W.D.F., E.F., L.Fritschi, D.F., GEMO.S.C., M.Gabrielson, P.Gaddam,  
 1121 M.GD., P.A.G., S.M.G., J.Garber, V.GB., M.GC., J.A.GS., M.M.G., M.GV., A.Gehrig,  
 1122 V.G., AM.G., G.G.G., G.G., A.KG., M.S.G., D.E.G., A.GN., P.Goodfellow, M.H.G.,  
 1123 G.I.GA., M.Grip, J.Gronwald, A.Grundy, D.GK., Q.G., P.Guénel, HEBON, L.H.,  
 1124 E.Hahnen, C.A.H., P.Hall, E.Hallberg, U.H., S.Hankinson, T.V.O.H., P.Harrington,  
 1125 S.N.H., J.M.H., C.S.H., A.Hein, S.Helbig, A.Henderson, J.H., P.Hillemanns,  
 1126 S.Hodgson, F.B.H., A.Hollestelle, M.J.H., B.Hoover, J.L.H., C.H., G.H., P.J.H., K.H.,  
 1127 D.J.H., N.Håkansson, E.N.I., C.I., M.I., L.I., A.J., P.J., R.J., W.J., UB.J., E.M.J., N.J.,  
 1128 M.J., A.JV., R.Kaaks, M.Kabisch, K.Kaczmarek, D.K., K.Kast, R.Keeman, M.J.K.,  
 1129 C.M.K., M.Keupers, S.Khan, E.K., J.I.K., J.A.K., I.K., V.K., P.K., V.N.K., T.A.K.,  
 1130 K.B.K., A.K., Y.L., F.Laloo, K.L., D.L., C.Lasset, C.Lazaro, L.IM., J.Lecarpentier,



1131 M.Lee, A.Lee, E.L., J.Lee, F.Lejbkowitz, F.Lesueur, J.Li, J.Lilyquist, A.Lincoln,  
1132 A.Lindblom, S.Lindström, J.Lissowska, WY.L., S.Loibl, J.Long, J.T.L., J.Lubinski,  
1133 C.Luccarini, M.Lush, AV.L., R.J.M., T.M., E.M., I.MK., A.Mannermaa, S.Manoukian,  
1134 J.E.M., S.Margolin, J.W.M.M., ME.M., K.Matsuo, D.M., S.Mazoyer, L.M., C.McLean,  
1135 H.MH., A.Meindl, P.M., H.M., K.Michailidou, A.Miller, N.M., R.L.M., G.M., M.M.,  
1136 K.Muir, A.M.M., C.Mulot, S.N., K.L.N., S.L.N., H.N., I.N., D.N., S.F.N., B.G.N., A.N.,  
1137 R.L.N., K.Offitt, E.O., O.I.O., J.E.O., H.O., C.O., K.Ong, J.C.O., N.O., A.O., L.O.,  
1138 VS.P., L.P., S.K.P., TW.PS., Y.PK., R.Peake, IS.P., B.Peissel, A.P., J.I.A.P., P.P.,  
1139 J.P., G.P., P.D.P.P., C.M.P., M.P., D.PK., B.Poppe, M.EP., R.Prentice, N.P., D.P.,  
1140 MA.P., K.P., B.R., P.R., N.R., J.Rantala, C.RF., H.S.R., G.R., V.R., K.R.,  
1141 A.Richardson, G.C.R., A.Romero, M.A.R., A.Rudolph, T.R., E.S., J.Sanders, D.P.S.,  
1142 S.Sangrajrang, E.J.S., D.F.S., M.K.S., R.K.S., M.J.Schoemaker, F.S., L.Schwentner,  
1143 P.Schürmann, C.Scott, R.J.S., S.Seal, L.Senter, C.Seynaeve, M.S., P.Sharma,  
1144 CY.S., H.Shimelis, M.J.Shrubsole, XO.S., L.E.S., J.Simard, C.F.S., C.Sohn,  
1145 P.Soucy, M.C.S., J.J.S., A.B.S., C.Stegmaier, J.Stone, D.SL., G.S., H.Surowy,  
1146 C.Sutter, A.S., C.I.S., R.M.T., Y.Y.T., J.A.T., M.R.T., MI.T., M.Tengström, S.H.T.,  
1147 M.B.T., A.T., M.Thomassen, D.L.T., K.Thöne, MG.T., L.T., M.Tischkowitz, A.E.T.,  
1148 R.A.E.M.T., I.T., D.T., M.Tranchant, T.T., K.Tucker, N.T., HU.U., C.V., D.vdB., L.V.,  
1149 R.VM., A.Vega, A.Viel, J.Vijai, L.W., Q.W., S.WG., B.W., C.R.W., J.N.W., C.W.,  
1150 J.W., A.S.W., J.T.W., W.W., R.W., A.W., A.H.W., X.R.Y., D.Y., D.Z., W.Z., A.Z., E.Z.,  
1151 K.K.Z., I.dSS., kConFab.AOCS.I., C.J.v.A., E.vR., A.M.W.vdO.

1152 All authors read and approved the final version of the manuscript

1153

#### 1154 **Competing Financial Interests**

1155 The authors confirm that they have no competing financial interests

1156 **Table 1: Ten novel loci associated with risk of estrogen receptor (ER)-negative breast cancer using meta-analysis of BCAC and**  
1157 **CIMBA data**

| Location | SNP         | Chr | Position  | Nearest gene     | Alleles <sup>#</sup> | BCAC ER-negative <sup>†</sup> |                  |                      | CIMBA <i>BRCA1</i> mutation carriers <sup>‡</sup> |                  |                      | Meta-analysis         | Heterogeneity        |
|----------|-------------|-----|-----------|------------------|----------------------|-------------------------------|------------------|----------------------|---|------------------|----------------------|-----------------------|----------------------|
|          |             |     |           |                  |                      | MAF                           | OR (95%CI)       | P-value              | MAF   | HR (95%CI)       | P-value              | P-value               | P-value <sup>*</sup> |
| 2p23.3   | rs200648189 | 2   | 24739694  | <i>NCOA1</i>     | CT/C                 | 0.19                          | 0.94 (0.91-0.97) | 4.7x10 <sup>-4</sup> | 0.20  | 0.88 (0.84-0.92) | 3.3x10 <sup>-7</sup> | 9.7x10 <sup>-9</sup>  | 2.0x10 <sup>-2</sup> |
| 6q23.1   | rs6569648   | 6   | 130349119 | <i>L3MBTL3</i>   | T/C                  | 0.23                          | 0.93 (0.90-0.95) | 4.3x10 <sup>-8</sup> | 0.22  | 0.94 (0.90-0.98) | 5.4x10 <sup>-3</sup> | 8.3x10 <sup>-10</sup> | 0.64                 |
| 8p23.3   | rs66823261  | 8   | 170692    | <i>RPL23AP53</i> | T/C                  | 0.23                          | 1.09 (1.06-1.12) | 5.6x10 <sup>-9</sup> | 0.22  | 1.02 (0.98-1.07) | 0.32                 | 3.3x10 <sup>-8</sup>  | 3.0x10 <sup>-2</sup> |
| 8q24.13  | rs17350191  | 8   | 124757661 | <i>ANXA13</i>    | C/T                  | 0.34                          | 1.07 (1.04-1.09) | 2.0x10 <sup>-8</sup> | 0.34  | 1.08 (1.04-1.12) | 1.9x10 <sup>-4</sup> | 1.7x10 <sup>-11</sup> | 0.81                 |
| 11q22.3  | rs11374964  | 11  | 108345515 | <i>KDELC2</i>    | G/GA                 | 0.42                          | 0.94 (0.92-0.96) | 3.6x10 <sup>-8</sup> | 0.43  | 0.91 (0.88-0.95) | 1.3x10 <sup>-6</sup> | 4.1x10 <sup>-13</sup> | 0.26                 |
| 11q22.3  | rs74911261  | 11  | 108357137 | <i>KDELC2</i>    | G/A                  | 0.02                          | 0.82 (0.75-0.89) | 2.3x10 <sup>-6</sup> | 0.02  | 0.74 (0.65-0.84) | 2.0x10 <sup>-6</sup> | 5.4x10 <sup>-11</sup> | 0.17                 |
| 16p13.3  | rs11076805  | 16  | 4106788   | <i>ADCY9</i>     | C/A                  | 0.25                          | 0.92 (0.90-0.95) | 2.2x10 <sup>-8</sup> | 0.25  | 0.96 (0.92-1.00) | 0.073                | 1.4x10 <sup>-8</sup>  | 0.14                 |
| 18q12.1  | rs36194942  | 18  | 25401204  | <i>CDH2</i>      | A/AT                 | 0.30                          | 0.94 (0.91-0.96) | 2.5x10 <sup>-7</sup> | 0.31  | 0.95 (0.91-0.99) | 1.4x10 <sup>-2</sup> | 1.4x10 <sup>-8</sup>  | 0.50                 |
| 19p13.2  | rs322144    | 19  | 11423703  | <i>TSPAN16</i>   | C/G                  | 0.47                          | 0.95 (0.93-0.97) | 2.4x10 <sup>-5</sup> | 0.46  | 0.92 (0.89-0.96) | 3.7x10 <sup>-5</sup> | 7.4x10 <sup>-9</sup>  | 0.23                 |
| 19q12    | rs113701136 | 19  | 30277729  | <i>CCNE1</i>     | C/T                  | 0.32                          | 1.07 (1.04-1.09) | 1.7x10 <sup>-7</sup> | 0.32  | 1.05 (1.01-1.09) | 1.2x10 <sup>-2</sup> | 6.8x10 <sup>-9</sup>  | 0.57                 |

1158 <sup>#</sup>More common allele listed first, minor allele second; <sup>†</sup>Combined data from 21,468 ER-negative cases and 100,594 controls of European ancestry from the Breast Cancer Association Consortium  
1159 (BCAC); <sup>‡</sup>Combined data from 18,908 *BRCA1* mutation carriers from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA), 9,414 of whom had developed breast cancer; <sup>\*</sup>Test for  
1160 heterogeneity in effect size for ER-negative disease and overall disease for *BRCA1* mutation carriers  
1161 Chr, chromosome; MAF, minor allele frequency; OR, odds ratio per copy of the minor allele; CI, confidence interval; HR, hazard ratio per copy of the minor allele  
1162  
1163  
1164  
1165

1166 **Table 2: Previously reported estrogen receptor (ER)-negative hits: replication using independent data from BCAC and combined**  
 1167 **results using all BCAC and CIMBA data**

| Location | SNP                    | Chr | Position  | Ref             | Nearest gene   | Alleles <sup>#</sup> | INDEPENDENT REPLICATION       |                  |                       | ALL AVAILABLE DATA COMBINED   |                       |                                 |                       |
|----------|------------------------|-----|-----------|-----------------|----------------|----------------------|-------------------------------|------------------|-----------------------|-------------------------------|-----------------------|---------------------------------|-----------------------|
|          |                        |     |           |                 |                |                      | BCAC ER-negative (OncoArray)* |                  |                       | BCAC ER-negative <sup>†</sup> |                       | CIMBA <i>BRCA1</i> <sup>‡</sup> |                       |
|          |                        |     |           |                 |                |                      | MAF                           | OR (95%CI)       | P-value               | OR (95%CI)                    | P-value               | HR (95%CI)                      | P-value               |
| 1q32.1   | rs6678914              | 1   | 202187176 | <sup>18</sup>   | <i>LGR6</i>    | G/A                  | 0.41                          | 0.94 (0.91-0.97) | 1.1x10 <sup>-4</sup>  | 0.92 (0.90-0.94)              | 2.6x10 <sup>-12</sup> | 0.98 (0.95-1.02)                | 0.31                  |
| 1q32.1   | rs4245739              | 1   | 204518842 | <sup>18</sup>   | <i>MDM4</i>    | A/C                  | 0.26                          | 1.12 (1.09-1.17) | 9.2x10 <sup>-11</sup> | 1.14 (1.11-1.16)              | 3.1x10 <sup>-23</sup> | 1.09 (1.04-1.13)                | 7.3x10 <sup>-5</sup>  |
| 2p24.1   | rs12710696             | 2   | 19320803  | <sup>18</sup>   | <i>MIR4757</i> | C/T                  | 0.37                          | 1.04 (1.00-1.07) | 2.5x10 <sup>-2</sup>  | 1.06 (1.04-1.09)              | 6.5x10 <sup>-8</sup>  | 1.01 (0.98-1.05)                | 0.49                  |
| 2p23.2   | rs4577244 <sup>*</sup> | 2   | 29120733  | <sup>29</sup>   | <i>WDR43</i>   | C/T                  | 0.34                          | 0.93 (0.89-0.96) | 9.6x10 <sup>-5</sup>  | 0.92 (0.90-0.95)              | 1.5x10 <sup>-9</sup>  | 0.92 (0.88-0.96)                | 1.3x10 <sup>-4</sup>  |
| 5p15.33  | rs10069690             | 5   | 1279790   | <sup>8,17</sup> | <i>TERT</i>    | C/T                  | 0.26                          | 1.19 (1.14-1.23) | 3.8x10 <sup>-21</sup> | 1.18 (1.15-1.21)              | 1.5x10 <sup>-35</sup> | 1.18 (1.14-1.23)                | 3.7x10 <sup>-16</sup> |
| 6q25.1   | rs3757322 <sup>*</sup> | 6   | 151942194 | <sup>28</sup>   | <i>ESR1</i>    | T/G                  | 0.32                          | 1.14 (1.10-1.18) | 5.5x10 <sup>-14</sup> | 1.15 (1.12-1.18)              | 2.8x10 <sup>-31</sup> | 1.14 (1.10-1.19)                | 2.9x10 <sup>-12</sup> |
| 6q25.2   | rs2747652 <sup>*</sup> | 6   | 152437016 | <sup>28</sup>   | <i>ESR1</i>    | C/T                  | 0.48                          | 0.92 (0.89-0.95) | 1.1x10 <sup>-7</sup>  | 0.91 (0.89-0.93)              | 1.9x10 <sup>-18</sup> | 1.00 (0.97-1.04)                | 0.96                  |
| 13q22.1  | rs6562760 <sup>*</sup> | 13  | 73957681  | <sup>29</sup>   | <i>KLF5</i>    | G/A                  | 0.24                          | 0.92 (0.88-0.95) | 5.0x10 <sup>-6</sup>  | 0.92 (0.90-0.95)              | 8.7x10 <sup>-10</sup> | 0.89 (0.86-0.93)                | 3.5x10 <sup>-7</sup>  |
| 16q12.2  | rs11075995             | 16  | 53855291  | <sup>18</sup>   | <i>FTO</i>     | T/A                  | 0.30                          | 1.07 (1.03-1.11) | 3.3x10 <sup>-4</sup>  | 1.09 (1.06-1.12)              | 1.0x10 <sup>-10</sup> | 1.01 (0.97-1.06)                | 0.49                  |
| 19p13.11 | rs67397200             | 19  | 17401404  | <sup>2,30</sup> | <i>ANKLE1</i>  | C/G                  | 0.32                          | 1.17 (1.13-1.21) | 7.0x10 <sup>-20</sup> | 1.17 (1.14-1.19)              | 2.7x10 <sup>-37</sup> | 1.18 (1.14-1.23)                | 2.7x10 <sup>-17</sup> |
| 20q11.21 | rs2284378              | 20  | 32588095  | <sup>11</sup>   | <i>RALY</i>    | C/T                  | 0.32                          | 0.99 (0.95-1.02) | 0.46                  | 1.03 (1.01-1.06)              | 1.7x10 <sup>-2</sup>  | 1.00 (0.97-1.04)                | 0.81                  |

1168 \*More common allele listed first, minor allele second; \*Includes Breast Cancer Association Consortium (BCAC) OncoArray data from 9,655 ER-negative cases and 45,494 controls cases and  
 1169 controls not included in previously published studies; <sup>†</sup>Combined data from 21,468 ER-negative cases and 100,594 controls of European ancestry from BCAC, which includes overlapping samples  
 1170 with previous publications for all SNPs; <sup>‡</sup>Combined data from 18,908 *BRCA1* mutation carriers from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA), 9,414 of whom had developed  
 1171 breast cancer - includes overlapping samples with previous publications for SNPs rs4577244, rs3757322, rs2747652 and rs6562760  
 1172 Chr, chromosome; Ref, publication(s) in reference list in which the association was identified; MAF, minor allele frequency; OR, odds ratio per copy of the minor allele; CI, confidence interval; HR,  
 1173 hazard ratio per copy of the minor allele  
 1174  
 1175

1176

1177 **Table 3: Associations for 10 novel and 10 previously reported (and replicated) ER-**  
1178 **negative breast cancer susceptibility loci, by triple-negative status**  
1179 **(BCAC data only: ER-negative cases\*, all controls))**

| Location  | SNP         | Triple-negative  |                       | Other ER-negative |                       | Heterogeneity         |
|---|-------------|------------------|-----------------------|-------------------|-----------------------|-----------------------|
|   |             | OR (95%CI)       | P-value               | OR (95%CI)        | P-value               | P-value*              |
| Loci identified by the present study                                    |             |                  |                       |                   |                       |                       |
| 2p23.3  | rs200648189 | 0.95 (0.90-1.00) | 4.8x10 <sup>-2</sup>  | 0.96 (0.91-1.03)  | 0.24                  | 0.36                  |
| 6q23.1  | rs6569648   | 0.93 (0.89-0.97) | 1.4x10 <sup>-3</sup>  | 0.93 (0.88-0.98)  | 5.6x10 <sup>-3</sup>  | 0.91                  |
| 8p23.3  | rs66823261  | 1.11 (1.05-1.16) | 3.3x10 <sup>-5</sup>  | 1.12 (1.07-1.19)  | 2.4x10 <sup>-5</sup>  | 0.91                  |
| 8q24.13   | rs17350191  | 1.07 (1.03-1.11) | 7.9x10 <sup>-4</sup>  | 1.07 (1.02-1.12)  | 4.0x10 <sup>-3</sup>  | 0.67                  |
| 11q22.3   | rs11374964  | 0.88 (0.85-0.91) | 1.9x10 <sup>-11</sup> | 0.99 (0.95-1.04)  | 0.75                  | 1.5x10 <sup>-5</sup>  |
| 11q22.3   | rs74911261  | 0.76 (0.66-0.87) | 1.1x10 <sup>-4</sup>  | 0.98 (0.84-1.13)  | 0.76                  | 3.0x10 <sup>-2</sup>  |
| 16p13.3   | rs11076805  | 0.91 (0.87-0.96) | 1.5x10 <sup>-4</sup>  | 0.95 (0.90-1.00)  | 4.5x10 <sup>-2</sup>  | 0.20                  |
| 18q12.1   | rs36194942  | 0.93 (0.89-0.96) | 2.4x10 <sup>-4</sup>  | 0.92 (0.88-0.97)  | 9.9x10 <sup>-4</sup>  | 0.94                  |
| 19p13.2   | rs322144    | 0.94 (0.91-0.98) | 5.9x10 <sup>-3</sup>  | 0.94 (0.90-0.98)  | 9.7x10 <sup>-3</sup>  | 0.68                  |
| 19q12   | rs113701136 | 1.10 (1.06-1.15) | 9.1x10 <sup>-7</sup>  | 1.07 (1.02-1.12)  | 4.4x10 <sup>-3</sup>  | 0.12                  |
| Previously reported loci (associations replicated by the present study) |             |                  |                       |                   |                       |                       |
| 1q32.1  | rs6678914   | 0.94 (0.91-0.98) | 2.1x10 <sup>-3</sup>  | 0.91 (0.87-0.95)  | 2.0x10 <sup>-5</sup>  | 0.45                  |
| 1q32.1  | rs4245739   | 1.18 (1.13-1.23) | 4.3x10 <sup>-15</sup> | 1.04 (1.00-1.10)  | 7.5x10 <sup>-2</sup>  | 6.5x10 <sup>-4</sup>  |
| 2p24.1  | rs12710696  | 1.07 (1.03-1.11) | 1.1x10 <sup>-3</sup>  | 1.04 (1.00-1.09)  | 6.1x10 <sup>-2</sup>  | 0.52                  |
| 2p23.2  | rs4577244   | 0.90 (0.86-0.94) | 5.3x10 <sup>-6</sup>  | 0.94 (0.89-0.99)  | 1.9x10 <sup>-2</sup>  | 0.15                  |
| 5p15.33   | rs10069690  | 1.28 (1.23-1.33) | 2.4x10 <sup>-33</sup> | 1.07 (1.02-1.12)  | 5.4x10 <sup>-3</sup>  | 5.6x10 <sup>-8</sup>  |
| 6q25.1  | rs3757322   | 1.15(1.10-1.19)  | 4.3x10 <sup>-12</sup> | 1.14(1.10-1.20)   | 4.8x10 <sup>-9</sup>  | 0.35                  |
| 6q25.2  | rs2747652   | 0.93(0.89-0.96)  | 5.7x10 <sup>-5</sup>  | 0.87(0.83-0.91)   | 2.9x10 <sup>-10</sup> | 9.6x10 <sup>-3</sup>  |
| 13q22.1   | rs6562760   | 0.94 (0.90-0.98) | 2.8x10 <sup>-3</sup>  | 0.92 (0.87-0.96)  | 8.8x10 <sup>-4</sup>  | 0.46                  |
| 16q12.2   | rs11075995  | 1.06 (1.02-1.11) | 6.5x10 <sup>-3</sup>  | 1.08 (1.03-1.13)  | 3.1x10 <sup>-3</sup>  | 0.81                  |
| 19p13.11  | rs67397200  | 1.27 (1.22-1.32) | 2.0x10 <sup>-32</sup> | 1.05 (1.01-1.10)  | 2.7x10 <sup>-2</sup>  | 4.7x10 <sup>-10</sup> |

1180 \*Combined Breast Cancer Association Consortium (BCAC) data from 6,877 triple-negative and 4,467 other ER-negative cases  
1181 and 83,700 controls; \*ER-negative case-only analysis, by triple-negative status; OR, odds ratio per copy of the minor allele;  
1182 CI, confidence interval  
1183  
1184

1185

1186

1187 **Table 4: Associations for 10 novel and 10 previously reported (and replicated) ER-negative breast cancer**  
1188 **susceptibility loci, by grade (BCAC data only: ER-negative cases\*, all controls)**

| Location  | SNP         | Grade 1          |                      | Grade 2          |                      | Grade 3          |                       | Heterogeneity<br>P-value* |
|---|-------------|------------------|----------------------|------------------|----------------------|------------------|-----------------------|---------------------------|
|   |             | OR (95%CI)       | P-value              | OR (95%CI)       | P-value              | OR (95%CI)       | P-value               |                           |
| Loci identified by the present study                                    |             |                  |                      |                  |                      |                  |                       |                           |
| 2p23.3  | rs200648189 | 1.11 (0.92-1.33) | 0.28                 | 0.95 (0.88-1.03) | 0.23                 | 0.96 (0.91-1.00) | 6.8x10 <sup>-2</sup>  | 0.70                      |
| 6q23.1  | rs6569648   | 0.93 (0.79-1.09) | 0.37                 | 0.93 (0.87-0.99) | 1.6x10 <sup>-2</sup> | 0.94 (0.91-0.98) | 3.8x10 <sup>-3</sup>  | 0.34                      |
| 8p23.3  | rs66823261  | 1.13 (0.96-1.34) | 0.14                 | 1.12 (1.04-1.19) | 1.2x10 <sup>-3</sup> | 1.10 (1.05-1.15) | 1.3x10 <sup>-5</sup>  | 0.11                      |
| 8q24.13   | rs17350191  | 1.16 (1.01-1.34) | 3.0x10 <sup>-2</sup> | 1.05 (0.99-1.11) | 0.10                 | 1.09 (1.05-1.12) | 4.1x10 <sup>-6</sup>  | 0.94                      |
| 11q22.3   | rs11374964  | 0.91 (0.79-1.04) | 0.16                 | 0.99 (0.94-1.05) | 0.85                 | 0.93 (0.90-0.96) | 1.3x10 <sup>-5</sup>  | 3.0x10 <sup>-2</sup>      |
| 11q22.3   | rs74911261  | 1.22 (0.81-1.84) | 0.35                 | 0.89 (0.73-1.07) | 0.21                 | 0.74 (0.65-0.85) | 7.4x10 <sup>-6</sup>  | 6.7x10 <sup>-4</sup>      |
| 16p13.3   | rs11076805  | 0.90 (0.76-1.06) | 0.21                 | 0.93 (0.87-0.99) | 3.2x10 <sup>-2</sup> | 0.92 (0.88-0.95) | 4.5x10 <sup>-5</sup>  | 0.71                      |
| 18q12.1   | rs36194942  | 0.97 (0.84-1.13) | 0.73                 | 0.93 (0.88-0.99) | 2.2x10 <sup>-2</sup> | 0.96 (0.92-0.99) | 2.3x10 <sup>-2</sup>  | 0.98                      |
| 19p13.2   | rs322144    | 0.94 (0.81-1.08) | 0.38                 | 0.95 (0.90-1.01) | 0.11                 | 0.96 (0.93-1.00) | 6.4x10 <sup>-2</sup>  | 0.48                      |
| 19q12   | rs113701136 | 1.02 (0.89-1.18) | 0.77                 | 1.06 (1.01-1.13) | 3.0x10 <sup>-2</sup> | 1.10 (1.06-1.14) | 2.5x10 <sup>-7</sup>  | 0.12                      |
| Previously reported loci (associations replicated by the present study) |             |                  |                      |                  |                      |                  |                       |                           |
| 1q32.1  | rs6678914   | 0.95 (0.83-1.09) | 0.46                 | 0.90 (0.85-0.95) | 9.3x10 <sup>-5</sup> | 0.92 (0.89-0.95) | 1.2x10 <sup>-6</sup>  | 0.75                      |
| 1q32.1  | rs4245739   | 1.02 (0.88-1.19) | 0.75                 | 1.05 (0.99-1.12) | 8.7x10 <sup>-2</sup> | 1.18 (1.14-1.22) | 2.5x10 <sup>-18</sup> | 4.3x10 <sup>-5</sup>      |
| 2p24.1  | rs12710696  | 1.08 (0.94-1.23) | 0.28                 | 1.10 (1.04-1.16) | 9.6x10 <sup>-4</sup> | 1.04 (1.01-1.08) | 1.6x10 <sup>-2</sup>  | 0.28                      |
| 2p23.2  | rs4577244   | 1.02 (0.88-1.20) | 0.77                 | 0.95 (0.89-1.01) | 9.4x10 <sup>-2</sup> | 0.90 (0.86-0.93) | 1.2x10 <sup>-7</sup>  | 4.0x10 <sup>-2</sup>      |
| 5p15.33   | rs10069690  | 0.96 (0.83-1.12) | 0.64                 | 1.07 (1.01-1.14) | 2.2x10 <sup>-2</sup> | 1.21 (1.17-1.26) | 1.5x10 <sup>-24</sup> | 7.3x10 <sup>-4</sup>      |
| 6q25.1  | rs3757322   | 1.16 (1.01-1.34) | 0.04                 | 1.13 (1.07-1.20) | 7.5x10 <sup>-6</sup> | 1.18 (1.14-1.22) | 4.5x10 <sup>-20</sup> | 0.16                      |
| 6q25.2  | rs2747652   | 0.86 (0.75-0.98) | 0.02                 | 0.92 (0.87-0.97) | 1.9x10 <sup>-3</sup> | 0.90 (0.87-0.93) | 1.6x10 <sup>-9</sup>  | 0.61                      |
| 13q22.1   | rs6562760   | 0.98 (0.84-1.15) | 0.82                 | 0.92 (0.87-0.98) | 1.4x10 <sup>-2</sup> | 0.91 (0.88-0.95) | 1.2x10 <sup>-5</sup>  | 0.52                      |
| 16q12.2   | rs11075995  | 1.16 (1.00-1.35) | 4.7x10 <sup>-2</sup> | 1.09 (1.02-1.15) | 7.5x10 <sup>-3</sup> | 1.08 (1.04-1.13) | 5.2x10 <sup>-28</sup> | 0.42                      |
| 19p13.11  | rs67397200  | 1.01 (0.87-1.16) | 0.91                 | 1.08 (1.02-1.14) | 9.8x10 <sup>-3</sup> | 1.22 (1.18-1.26) | 5.3x10 <sup>-37</sup> | 1.3x10 <sup>-3</sup>      |

\*Combined Breast Cancer Association Consortium (BCAC) data from 492 grade 1, 3,243 grade 2 and 8,568 grade 3 cases and 82,347 controls; \* ER-negative case-only analysis of BCAC data, by grade (trend test, 1df); OR, odds ratio per copy of the minor allele; CI, confidence interval

1189  
1190  
1191

**Figure legends**

**Figure 1. Genomic region around the two independent ER negative risk associated variants, 11\_108345515\_G\_A (rs11374964) and 11\_108357137\_G\_A (rs74911261).** One Mb region showing **statistical significance of all genotyped and imputed SNPs (regional Manhattan plot)** and positions of candidate causal variants for two independent signals (shown as red or blue tick marks) in relation to RefSeq annotated genes. Missense variants are labelled with asterisks. Breast cell enhancers overlapping candidate SNPs predicted to target nearby genes by IM-PET (He et al., PNAS 2014) are depicted as black bars. Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells overlapping candidate variants are depicted as boxes connected by thin lines and shaded to reflect the confidence score of the interaction. Epigenomic features (derived from publicly available transcription factor ChIP-seq, histone modification ChIP-seq and DNase hypersensitive site-seq) that overlap candidate variants are shown as red or blue segments, depending on the signal which is intersected. Density tracks show the summed occurrence of transcription factor ChIP-seq, histone modification ChIP-seq, and DNase hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project chromatin state models for HMEC and myoepithelial cells grouped into enhancer, promoter or transcribed annotations are shown as yellow, red or green segments, respectively. Transcript levels in MCF7 and HMEC cells are represented by histograms depicting the mean of combined and normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C (Rao et al., Cell 2014) chromatin interactions are represented by black and blue arcs, respectively. Published GWAS signals from the NHGRI catalog are shown as green ticks. The last track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and uninterrogated, common (dbSNP 138 EUR MAF > 1%) SNPs as red ticks. Supplementary Table 5 provides full details of functional annotation for each risk locus including a link to the UCSC Genome Browser, which allows these features to be examined in more detail.

**Supplementary Figure 1. Manhattan plot of associations with breast cancer risk for all imputed and genotyped SNPs using combined data from ER-negative cases and controls and *BRCA1* mutation carriers, before (A) and after (B) excluding known breast cancer susceptibility loci.**

**Supplementary Figure 2. Quantile-quantile plot of associations with breast cancer risk for all imputed and genotyped SNPs using combined data from ER-negative cases and controls and *BRCA1* mutation carriers.**

**Supplementary Figure 3. Genomic region around the ER negative risk associated variant 2\_24739694\_CT\_T (rs200648189).** One Mb region showing statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) and positions of candidate causal variants in relation to RefSeq annotated genes. Breast cell enhancers overlapping candidate SNPs predicted to target nearby genes by methods including IM-PET<sup>50</sup> and Hnisz<sup>51</sup> are depicted as black bars. Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells overlapping candidate variants are depicted as boxes connected by thin lines and shaded to reflect the confidence score of the interaction. Epigenomic features (derived from publicly available transcription factor ChIP-seq, histone modification ChIP-seq and DNase hypersensitive site-seq) that overlap candidate variants are shown as red segments. Density tracks show the summed occurrence of transcription factor ChIP-seq, histone modification ChIP-seq, and DNase hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project chromatin state models for HMEC and myoepithelial cells grouped into enhancer, promoter or transcribed annotations are shown as yellow, red or green segments, respectively. Transcript levels in MCF7 and HMEC cells are represented by histograms depicting the mean of combined and normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET (ENCODE) chromatin interactions are represented by black arcs. Published GWAS signals from the NHGRI catalog are shown as green ticks. The last track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks.

**Supplementary Figure 4. Genomic region around the ER negative risk associated variant 6\_130349119\_T\_C (rs6569648).** One Mb region showing statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) and positions of candidate causal variants in relation to RefSeq annotated genes. Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells overlapping candidate variants are depicted as boxes connected by thin lines and shaded to reflect the confidence score of the interaction. Epigenomic features (derived from publicly available transcription factor ChIP-seq and histone modification ChIP-seq) which overlap candidate variants are shown as red segments. Density tracks show the summed occurrence of transcription factor ChIP-seq, histone modification ChIP-seq, and DNase hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project chromatin state models for HMEC and myoepithelial cells grouped into enhancer, promoter or transcribed annotations are shown as yellow, red or green segments, respectively. Transcript levels in MCF7 and HMEC cells are represented by histograms depicting the mean of combined and normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C<sup>52</sup> chromatin interactions are represented by black and blue arcs, respectively. Published GWAS signals from the NHGRI catalog are shown as green ticks. The last track shows tested Oncoarray SNPs (genotyped or imputed)

1270 as black ticks and uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as  
1271 red ticks.

1272 **Supplementary Figure 5. Genomic region around the ER negative risk**  
1273 **associated variant 8\_170692\_T\_C (rs66823261).** One Mb region showing  
1274 **statistical significance of all genotyped and imputed SNPs (regional Manhattan plot)**  
1275 **and** positions of candidate causal variants in relation to RefSeq annotated genes.  
1276 Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells  
1277 overlapping candidate variants are depicted as boxes connected by thin lines and  
1278 shaded to reflect the confidence score of the interaction. Epigenomic features  
1279 derived from publicly available transcription factor ChIP-seq which overlap candidate  
1280 variants are shown as red segments. Density tracks show the summed occurrence  
1281 of transcription factor ChIP-seq, histone modification ChIP-seq, and DNase  
1282 hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project  
1283 chromatin state models for HMEC and myoepithelial cells grouped into enhancer,  
1284 promoter or transcribed annotations are shown as yellow, red or green segments,  
1285 respectively. Transcript levels in MCF7 and HMEC cells are represented by  
1286 histograms depicting the mean of combined and normalised RNA-seq expression  
1287 level at each genomic position . All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C<sup>52</sup>  
1288 chromatin interactions are represented by black and blue arcs, respectively.  
1289 Published GWAS signals from the NHGRI catalog are shown as green ticks. The last  
1290 track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and  
1291 uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks.

1292 **Supplementary Figure 6. Genomic region around the ER negative risk**  
1293 **associated variant 8\_124757661\_C\_T (rs17350191).** One Mb region showing  
1294 **statistical significance of all genotyped and imputed SNPs (regional Manhattan plot)**  
1295 **and** positions of candidate causal variants in relation to RefSeq annotated genes.  
1296 Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells  
1297 overlapping candidate variants are depicted as boxes connected by thin lines and  
1298 shaded to reflect the confidence score of the interaction. Epigenomic features  
1299 (derived from publicly available transcription factor ChIP-seq, histone modification  
1300 ChIP-seq and DNase hypersensitive site-seq) that overlap candidate variants are  
1301 shown as red segments. Density tracks show the summed occurrence of  
1302 transcription factor ChIP-seq, histone modification ChIP-seq, and DNase  
1303 hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project  
1304 chromatin state models for HMEC and myoepithelial cells grouped into enhancer,  
1305 promoter or transcribed annotations are shown as yellow, red or green segments,  
1306 respectively. Transcript levels in MCF7 and HMEC cells are represented by  
1307 histograms depicting the mean of combined and normalised RNA-seq expression  
1308 level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C<sup>52</sup>  
1309 chromatin interactions are represented by black and blue arcs, respectively.  
1310 Published GWAS signals from the NHGRI catalog are shown as green ticks. The last  
1311 track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and  
1312 uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks.

1313 **Supplementary Figure 7. Genomic region around the ER negative risk**  
1314 **associated variant 16\_4106788\_C\_A (rs11076805).** One Mb region showing  
1315 **statistical significance of all genotyped and imputed SNPs (regional Manhattan plot)**  
1316 **and** positions of candidate causal variants in relation to RefSeq annotated genes.  
1317 Breast cell enhancers overlapping candidate SNPs predicted to target nearby genes



by PreSTIGE<sup>53</sup> are depicted as black bars. Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells overlapping candidate variants are depicted as boxes connected by thin lines and shaded to reflect the confidence score of the interaction. Epigenomic features (derived from publicly available transcription factor ChIP-seq and histone modification ChIP-seq) which overlap candidate variants are shown as red segments. Density tracks show the summed occurrence of transcription factor ChIP-seq, histone modification ChIP-seq, and DNase hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project chromatin state models for HMEC and myoepithelial cells grouped into enhancer, promoter or transcribed annotations are shown as yellow, red or green segments, respectively. Transcript levels in MCF7 and HMEC cells are represented by histograms depicting the mean of combined and normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C<sup>52</sup> chromatin interactions are represented by black and blue arcs, respectively. Published GWAS signals from the NHGRI catalog are shown as green ticks. The last track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks.

**Supplementary Figure 8. Genomic region around the ER negative risk associated variant 18\_25401204\_A\_AT (rs36194942).** One Mb region showing statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) and positions of candidate causal variants in relation to RefSeq annotated genes. Epigenomic features (derived from publicly available transcription factor ChIP-seq, histone modification ChIP-seq and DNase hypersensitive site-seq) that overlap candidate variants are shown as red segments. Density tracks show the summed occurrence of transcription factor ChIP-seq, histone modification ChIP-seq, and DNase hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project chromatin state models for HMEC and myoepithelial cells grouped into enhancer, promoter or transcribed annotations are shown as yellow, red or green segments, respectively. Transcript levels in MCF7 and HMEC cells are represented by histograms depicting the mean of combined and normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C<sup>52</sup> chromatin interactions are represented by black and blue arcs, respectively. Published GWAS signals from the NHGRI catalog are shown as green ticks. The last track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks.

**Supplementary Figure 9. Genomic region around the ER negative risk associated variant 19\_11423703\_C\_G (rs322144).** One Mb region showing statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) and positions of candidate causal variants in relation to RefSeq annotated genes. Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells overlapping candidate variants are depicted as boxes connected by thin lines and shaded to reflect the confidence score of the interaction. Epigenomic features (derived from publicly available transcription factor ChIP-seq and DNase hypersensitive site-seq) that overlap candidate variants are shown as red segments. Density tracks show the summed occurrence of transcription factor ChIP-seq, histone modification ChIP-seq, and DNase hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project chromatin state models for HMEC and myoepithelial cells grouped into enhancer, promoter or transcribed annotations are shown as yellow, red or green segments, respectively. Transcript levels in MCF7

and HMEC cells are represented by histograms depicting the mean of combined and normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C<sup>52</sup> chromatin interactions are represented by black and blue arcs, respectively. Published GWAS signals from the NHGRI catalog are shown as green ticks. The last track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks.

**Supplementary Figure 10. Genomic region around the ER negative risk associated variant 19\_30277729\_C\_T (rs113701136).** One Mb region showing statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) and positions of candidate causal variants in relation to RefSeq annotated genes. Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells overlapping candidate variants are depicted as boxes connected by thin lines and shaded to reflect the confidence score of the interaction. Epigenomic features (derived from publicly available transcription factor ChIP-seq, histone modification ChIP-seq and DNase hypersensitive site-seq) that overlap candidate variants are shown as red segments. Density tracks show the summed occurrence of transcription factor ChIP-seq, histone modification ChIP-seq, and DNase hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project chromatin state models for HMEC and myoepithelial cells grouped into enhancer, promoter or transcribed annotations are shown as yellow, red or green segments, respectively. Transcript levels in MCF7 and HMEC cells are represented by histograms depicting the mean of combined and normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C<sup>52</sup> chromatin interactions are represented by black and blue arcs, respectively. Published GWAS signals from the NHGRI catalog are shown as green ticks. The last track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks.

**Supplementary Figure 11. Regional eQTL association plot for all variants within 1 Mb of gene *L3MTBL3* and expression of gene *L3MTBL3*.** Red dots indicate candidate causal risk variants from the meta-analysis of BCAC ER-negative case-control and CIMBA *BRCA1* mutation carrier data.

**Supplementary Figure 12. Regional eQTL association plot for all variants within 1 Mb of gene *CDH2* and expression of gene *CDH2*.** Red dots indicate candidate causal risk variants from the meta-analysis of BCAC ER-negative case-control and CIMBA *BRCA1* mutation carrier data.

**Supplementary Figure 13. Enrichment map for pathways enriched in susceptibility to ER-negative breast cancer.** (A) Enriched pathways (enrichment score [ES]>0.4086) are grouped into themes and annotated with genes that appeared to drive the enrichment signal (see Online Methods). (B) Zoom-in on the adenylate cyclase theme. Shaded circles represent pathways (darker red indicates higher ES and larger size denotes a greater number of genes in the pathway) and green lines connect those that are most similar in terms of gene set overlap (>70%), with thicker lines denoting greater similarity.

